

# Antibiotic-resistant bacteria show widespread collateral sensitivity to antimicrobial peptides

Viktória Lázár<sup>1,8,9</sup>, Ana Martins<sup>1,9</sup>, Réka Spohn<sup>1</sup>, Lejla Daruka<sup>1</sup>, Gábor Grézal<sup>1</sup>, Gergely Fekete<sup>1</sup>, Mónika Számel<sup>1</sup>, Pramod K Jangir<sup>1</sup>, Bálint Kintses<sup>1</sup>, Bálint Csörgő<sup>1</sup>, Ákos Nyerges<sup>1</sup>, Ádám Györkei<sup>1</sup>, András Kincses<sup>2</sup>, András Dér<sup>2</sup>, Fruzsina R Walter<sup>3</sup>, Mária A Deli<sup>3</sup>, Edit Urbán<sup>4</sup>, Zsófia Hegedűs<sup>5</sup>, Gábor Olajos<sup>5</sup>, Orsolya Méhi<sup>1</sup>, Balázs Bálint<sup>6</sup>, István Nagy<sup>6,7</sup>, Tamás A Martinek<sup>5</sup>, Balázs Papp<sup>1\*</sup> and Csaba Pál<sup>1\*</sup>

**Antimicrobial peptides are promising alternative antimicrobial agents. However, little is known about whether resistance to small-molecule antibiotics leads to cross-resistance (decreased sensitivity) or collateral sensitivity (increased sensitivity) to antimicrobial peptides. We systematically addressed this question by studying the susceptibilities of a comprehensive set of 60 antibiotic-resistant *Escherichia coli* strains towards 24 antimicrobial peptides. Strikingly, antibiotic-resistant bacteria show a high frequency of collateral sensitivity to antimicrobial peptides, whereas cross-resistance is relatively rare. We identify clinically relevant multidrug-resistance mutations that increase bacterial sensitivity to antimicrobial peptides. Collateral sensitivity in multidrug-resistant bacteria arises partly through regulatory changes shaping the lipopolysaccharide composition of the bacterial outer membrane. These advances allow the identification of antimicrobial peptide-antibiotic combinations that enhance antibiotic activity against multidrug-resistant bacteria and slow down de novo evolution of resistance. In particular, when co-administered as an adjuvant, the antimicrobial peptide glycine-leucine-amide caused up to 30-fold decrease in the antibiotic resistance level of resistant bacteria. Our work provides guidelines for the development of efficient peptide-based therapies of antibiotic-resistant infections.**

Evolution of resistance towards antibiotics, or any other drug, can simultaneously increase (cross-resistance) or decrease (collateral sensitivity) fitness to multiple other drugs<sup>1–5</sup>. The molecular mechanisms driving cross-resistance are well-described<sup>2,4,5</sup>. In contrast, it remains unclear how frequently genetic adaptation to a single drug increases bacterial sensitivity to other drugs and what the underlying molecular mechanisms of collateral sensitivity are. This issue is important as collateral sensitivity could direct future multidrug therapeutic strategies<sup>6</sup>. However, such strategies are limited by the scarcity of available drug pairs showing collateral sensitivity that could also be used in clinical settings. Clearly, the concept of collateral sensitivity needs to be expanded by studying a broader scope of antimicrobial agents.

Here, we systematically study the effect of antibiotic-resistance mechanisms on susceptibility to antimicrobial peptides, a promising class of new antibacterial compounds. Antimicrobial peptides are short peptides with a broad spectrum of antibacterial activities<sup>7</sup>. Such peptides are found among all classes of life, and are part of the defence mechanisms against microbial pathogens<sup>7</sup>. Because antimicrobial peptides have diverse chemical features and cellular targets, they are promising antibacterial agents<sup>8,9</sup>. However, the degree of similarity between the resistance mechanisms to peptides and to

small-molecule antibiotics remains disputed<sup>10</sup>. This is relevant as some peptides have now reached advanced stages in clinical trials<sup>8</sup>.

We had previously initiated laboratory evolutionary experiments starting with a single clone of *Escherichia coli* K-12<sup>2,3</sup>. Parallel evolving populations were exposed to gradually increasing concentrations of 1 of 12 clinically relevant antibiotics (Supplementary Table 1), leading to up to 328-fold increases in their minimum inhibitory concentrations (MICs) relative to the wild type<sup>2</sup>. The resistance levels were equal to or above the European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints, and 52% of the antibiotic-resistant strains showed resistance to multiple antibiotics<sup>2</sup>. Here, we focus on a representative set of 60 antibiotic-resistant strains (5 strains per antibiotic) that have been subjected to whole-genome sequence analysis in order to identify the molecular mechanisms underlying antibiotic resistance<sup>2</sup>. Many of the observed mutations have also been detected in clinical drug-resistant isolates, and are known to target cellular systems involved in inner and outer membrane transport and permeability (for example, efflux pumps, porins) and cell envelope biogenesis<sup>2</sup>.

We hypothesized that such membrane-altering antibiotic-resistance mutations not only influence susceptibility to other antibiotics, but to antimicrobial peptides as well. Why should this be so?

<sup>1</sup>Synthetic and Systems Biology Unit, Institute of Biochemistry, Biological Research Centre, Hungarian Academy of Sciences, Szeged, Hungary.

<sup>2</sup>Biomolecular Electronics Research Group, Bionanoscience Unit, Institute of Biophysics, Biological Research Centre, Hungarian Academy of Sciences, Szeged, Hungary. <sup>3</sup>Biological Barriers Research Group, Institute of Biophysics, Biological Research Centre, Hungarian Academy of Sciences, Szeged, Hungary.

<sup>4</sup>Institute of Clinical Microbiology, Albert Szent-Györgyi Medical and Pharmaceutical Center, Faculty of Medicine, University of Szeged, Szeged, Hungary. <sup>5</sup>Institute of Pharmaceutical Analysis, University of Szeged, Szeged, Hungary. <sup>6</sup>SeqOmics Biotechnology Ltd, Mórahalom, Hungary.

<sup>7</sup>Sequencing Platform, Institute of Biochemistry, Biological Research Centre of the Hungarian Academy of Sciences, Szeged, Hungary. <sup>8</sup>Present address:

Faculty of Biology, Technion – Israel Institute of Technology, Haifa, Israel. <sup>9</sup>These authors contributed equally to this work: Viktória Lázár and Ana Martins.

\*e-mail: [pappb@brc.hu](mailto:pappb@brc.hu); [cpal@brc.hu](mailto:cpal@brc.hu)

The action of most antimicrobial peptides relies on the interaction between the positively charged peptide and the negatively charged membrane components, for two reasons. First, the structural and physicochemical properties of antimicrobial peptides (for example, net positive charge, hydrophobicity) and their capacity to adopt an amphipathic conformation upon membrane binding influence this interaction<sup>8,11,12</sup>. Second, the insertion of antimicrobial peptides into the hydrophobic core of the membrane depends on the general properties of the bacterial outer membrane<sup>11,12</sup>. For instance, lipopolysaccharide (LPS) composition has a major impact on the killing efficiency of cationic antimicrobial peptides<sup>13</sup>. For these reasons, it is plausible that membrane-affecting antibiotic-resistance mutations shape genetic susceptibility to antimicrobial peptides. However, no systematic study has been devoted to address this problem in detail.

Here, we first measured the susceptibility of the 60 antibiotic-resistant strains<sup>2,3</sup> against a set of 24 antimicrobial peptides of diverse origin and various modes of action. We found widespread bacterial collateral sensitivity towards antimicrobial peptides. Analysis of the mutational and transcriptome profiles of the antibiotic-resistant strains revealed that antibiotic-resistance mutations increase sensitivity to peptides via regulatory changes in LPS biosynthesis. The consequent alteration in the surface charge presumably strengthens the interaction of cationic antimicrobial peptides with the outer membrane, and thus enhances the killing efficiency of these peptides. Finally, we demonstrated that the antimicrobial peptide glycine-leucine-amide (PGLA), when co-administered as an adjuvant, restores antibiotic activity against resistant bacteria and slows down antibiotic-resistance evolution.

## Results

**Widespread collateral sensitivity to antimicrobial peptides.** To study whether antibiotic resistance in *E. coli* leads to cross-resistance or collateral sensitivity towards antimicrobial peptides, we measured the changes in the susceptibilities of 60 antibiotic-resistant strains to a set of 24 peptides. Peptides were chosen based on the following criteria: diverse sources (synthetic/natural), different putative mechanisms of action, structural diversity, and clinical relevance (Supplementary Table 2). The obtained results allowed us to chart the map of cross-resistance/collateral sensitivity of the antibiotic-resistant strains towards the 24 antimicrobial peptides, and identify several general patterns (Fig. 1a, Supplementary Table 3).

First, cross-resistance to antimicrobial peptides was relatively rare: only 12% of all possible antibiotic-resistant strain and peptide pairs showed cross-resistance, whereas 31% showed collateral sensitivity. The observed strength of cross-resistance and collateral sensitivity was usually a twofold change in MIC relative to the wild type (Supplementary Fig. 1, Supplementary Table 4). In typical clinical settings, drug concentrations well above the wild-type MIC are applied<sup>14</sup>. Therefore, we asked how collateral sensitivity shapes the killing kinetics with peptides applied at a concentration 10–15-fold above the wild-type MIC. We focused on five resistant strains that showed collateral sensitivity to at least one of the peptides studied (Fig. 2a–c). Upon antimicrobial peptide stress, collateral-sensitive populations showed a far more rapid decline in size than the wild type. For example, 15 minutes of protamine (PROA) exposure nearly completely eradicated ciprofloxacin (CPR)-resistant bacteria, whereas the size of the wild-type population declined only by tenfold (Fig. 2a).

Second, collateral sensitivity and cross-resistance patterns clustered the antimicrobial peptides into three main groups (Fig. 1) with major differences in their physicochemical properties and modes of action. Antimicrobial peptides belonging to the P1 and P3 groups generally insert themselves into membrane bilayers to form pores and thus induce cell lysis (pore formers). However, these two groups differ both in their physicochemical properties and their interactions with antibiotic-resistant strains: P1 peptides

have lower isoelectric point and hydrophobicity index compared to P3 peptides (see Supplementary Fig. 2) and are depleted in cross-resistance and collateral sensitivity interactions, whereas collateral sensitivity towards P3 peptides is prevalent (Fig. 1a, Supplementary Table 5).

On the contrary, members of the P2 group typically penetrate into the cell and have intracellular targets (Supplementary Table 2). Unlike P1 and P3, the P2 group consists of proline-rich peptides that are characterized by unstable secondary peptide structure, high propensity for aggregation in aqueous solutions and relatively low aliphatic and hydrophobicity indices (Supplementary Fig. 3, Supplementary Table 6). Notably, cross-resistance towards P2 peptides is frequent compared to the other peptide groups (Fig. 1a, Supplementary Table 5).


Third, not all peptides were equally effective against antibiotic-resistant bacteria (Fig. 1b). Most notably, 82% of the antibiotic-resistant strains showed collateral sensitivity to PGLA, a member of the magainin family<sup>15</sup> (Fig. 1c). Consistent with their conserved evolutionary roles, human peptides, such as human beta defensin 3 (HBD3) and LL-37 cathelicidin (LL37), also showed few, if any, cross-resistance interactions (Fig. 1b, Supplementary Table 3). In contrast, various antibiotic-resistant strains showed cross-resistance to the proline-rich peptide apidaecin IB (AP). This result could be of clinical relevance, as AP is currently being investigated for therapeutic usage<sup>16</sup>.

We next tested the evolutionary conservation of collateral sensitivity by measuring the susceptibility of clinically-derived *E. coli* strains towards nine relevant antimicrobial peptides. Three clinical isolates were previously allowed to adapt to three different antibiotics (gentamicin, nalidixic acid (NAL) and ampicillin (AMP)) in the laboratory<sup>1</sup>. The peptide susceptibility profiles of these antibiotic-resistant strains showed good agreement with those presented in Fig. 1, indicating that collateral sensitivity is partly conserved across multiple genetic backgrounds (Supplementary Table 7).


**Aminoglycoside resistance induces cross-resistance to antimicrobial peptides.** Whereas cross-resistance to antimicrobial peptides was generally much less common than collateral sensitivity, the distribution of cross-resistance interactions was far from random (Fig. 1c). Specifically, strains resistant to aminoglycosides (tobramycin (TOB) and kanamycin (KAN)) showed cross-resistance to proline-rich peptides (P2 group, see Fig. 1a). These strains are reminiscent of aminoglycoside-resistant small-colony variants observed in clinical settings, as they accumulated membrane potential-altering mutations<sup>17</sup>. Moreover, they uniquely carried a loss-of-function mutation in the gene encoding the inner membrane transport protein *sbmA*<sup>2</sup> (Fig. 1a). *sbmA* is commonly mutated in response to aminoglycoside stress<sup>18</sup>, and is involved in the uptake of proline-rich peptides<sup>10,19</sup>.

Here, we asked whether a loss-of-function mutation in *sbmA* contributes to the observed cross-resistance pattern of the aminoglycoside-resistant strains against P2 peptides. As expected, deletion of this gene in *E. coli* BW25113 and in the clinical isolate *E. coli* ATCC 25922 conferred mild, but significant, resistance to both aminoglycosides and proline-rich peptides (Table 1, Supplementary Text 1, Supplementary Fig. 4a–f). For a possible contribution of other mutations to cross-resistance between aminoglycosides and proline-rich peptides, see Supplementary Text 2.

**Multidrug-resistance mutations confer collateral sensitivity to antimicrobial peptides.** We next explored the mutations underlying collateral sensitivity. To this end, we first clustered the antibiotic-resistant strains based on their peptide susceptibility profiles and compiled the set of mutations shared among them (Fig. 1a). This procedure revealed four main groups of resistant strains (S1–S4), each of them carrying distinct sets of mutations.



**Fig. 1 | Susceptibility profiles of 60 laboratory-evolved antibiotic-resistant *E. coli* strains.** **a**, Hierarchical clustering of 60 antibiotic-resistant strains (rows) and a set of 24 antimicrobial peptides (columns) based on the cross-resistance and collateral sensitivity interactions between them (for abbreviations of antibiotics and antimicrobial peptides see Supplementary Tables 1 and 2, respectively). Hierarchical clustering was performed separately on rows and columns, using Ward's method<sup>67</sup>. Black squares on the right side of each antibiotic-resistant strain denote previously identified mutations in antibiotic-resistance genes<sup>2,3</sup> that were significantly enriched in one or more strain clusters ( $P < 0.05$ , two-sided Fisher's exact test). S1 strains were enriched in *envZ*, *ompR* and *ompC* mutations, whereas S3 strains were enriched in *marR* mutations ( $P < 0.05$  for all cases, two-sided Fisher's exact test). While S3 strains show widespread collateral sensitivity to antimicrobial peptides, especially to P1 and P3 peptides, aminoglycoside-resistant strains (S4) show extensive cross-resistance to proline-rich peptides (P2) ( $P < 0.0001$ , two-sided Fisher's exact test). **b**, Efficiency of antimicrobial peptides against antibiotic-resistant bacteria expressed as the percentage of strains showing collateral sensitivity (blue), no interaction (white) or cross-resistance (orange) against each peptide. A total of 56–60 strains per antimicrobial peptide were employed for the analysis. **c**, Relative frequency of collateral sensitivity and cross-resistance interactions towards antimicrobial peptides upon adaptation to single antibiotics ( $n = 5$  strains per antibiotic). The frequency of interactions for each peptide was calculated by counting the number of cross-resistance (orange), no interaction (white) and collateral sensitivity (blue) interactions displayed by all strains adapted to a given antibiotic. Antibiotic modes of action are shown on the top of the figure. 30S<sup>AG</sup> refers to aminoglycosides. Asterisks (\*) mark significant deviations from hypergeometric distribution models calculated from all the interactions of all peptide-strain combinations separately for cross-resistance and collateral sensitivity, respectively. Strains adapted to DOX and TET were depleted, whereas strains adapted to TOB and KAN were enriched in cross-resistance interactions towards peptides ( $P = 0.005$ ,  $P < 0.008$ ,  $P = 0.003$  and  $P < 0.001$ , respectively, two-sided Fisher's combined probability test). Furthermore, strains adapted to ERY and TRM were significantly depleted in collateral sensitivity interactions ( $P = 0.003$  and  $P < 0.001$ , respectively, two-sided Fisher's combined probability test).



**Fig. 2 | Survival of collateral-sensitive antibiotic-resistant strains under lethal antimicrobial peptide stress. a–c,** The wild-type and antibiotic-resistant strains were exposed to high concentrations of antimicrobial peptides: the TET-resistant TET3 and the CPR-resistant CPR7 strains were exposed to 15-fold (3,000  $\mu\text{g ml}^{-1}$ ) MIC of PROA (**a**); the CPR-resistant CPR7 and the TOB-resistant TOB8 were exposed to 10-fold MIC (125  $\mu\text{g ml}^{-1}$ ) of IND (**b**); and the DOX-resistant DOX3 and the KAN-resistant KAN8 were exposed to 15-fold MIC (1,500  $\mu\text{g ml}^{-1}$ ) of PGLA (**c**). All antibiotic-resistant strains exhibited collateral sensitivity towards the applied peptide. **d,** A strain containing a single point mutation in *marR* (*marR*<sup>\*</sup>) was also exposed to 15-fold MIC of PGLA. This strain exhibits resistance to multiple antibiotics and collateral sensitivity to many of the peptides tested, including PGLA (Table 1). Cells were incubated with the particular peptide for 120 minutes. Samples were taken at defined time points and plated in lysogeny broth agar plates. Percentage of survival was calculated by counting the colony forming units (CFUs). Each data point shows the mean  $\pm$  s.e.m. of three biological replicates.

Strains belonging to group S1 were adapted to a range of different antibiotics, including cefoxitin (FOX), a cell-wall inhibitor, and nitrofurantoin (NIT) that targets several biochemical processes within the bacterial cell. However, they mostly exhibited collateral sensitivity to P3 peptides (Fig. 1a) and accumulated mutations in a similar set of genes. Enrichment analysis revealed that they typically carry mutations in the EnvZ/OmpR two-component regulatory system and in the outer membrane porin C (*ompC*)<sup>2</sup>; for details and statistics, see Fig. 1a. The EnvZ/OmpR system, through regulating the outer membrane porin genes *ompC* and *ompF*, mediates bacterial defence against antimicrobials by reducing the uptake of hydrophilic antibiotics<sup>20,21</sup>. Consistent with a causal role in collateral sensitivity, inserting an *ompC* loss-of-function mutation into wild-type *E. coli* conferred resistance to NIT and cell-wall inhibitor antibiotics, and simultaneously increased sensitivity to multiple antimicrobial peptides (see Table 1 and Supplementary Text 3 for a proposed mechanism).

We further identified a group of strains (S3, see Fig. 1a) that typically showed collateral sensitivity to pore-forming peptides (clusters P1 and P3). These strains carry mutations in *marR*, a transcriptional repressor of antibiotic stress response<sup>22</sup> (Fig. 1a). MarR represses the *mar* regulon that controls genes involved in membrane permeability and efflux of toxic chemicals<sup>23</sup>. Elevated expression of the *mar* regulon is frequently found in multidrug-resistant clinical isolates<sup>23</sup>. Insertion of a recurrently observed *marR* mutation<sup>2</sup> either into wild-type *E. coli* BW25113 or into the antibiotic-sensitive clinical isolate *E. coli* ATCC 25922 conferred mild, but significant, resistance to several antibiotics, and simultaneously enhanced sensitivity

to P3 antimicrobial peptides (Table 1, Fig. 2d, Supplementary Text 1, Supplementary Fig. 4g–j).

Overall, these findings demonstrate that collateral sensitivity to antimicrobial peptides is induced by multidrug-resistant mutations that appeared repeatedly in response to various antibiotic stresses (for further examples, see Table 1).

**Gene expression changes in LPS biosynthesis contribute to collateral sensitivity.** We next hypothesized that changes in the outer membrane composition of antibiotic-resistant bacteria underlie the observed collateral sensitivity to antimicrobial peptides.

To test this possibility, we started by determining the sensitivity of the antibiotic-resistant strains to bile acid, a membrane-damaging agent. As expected, 75% of the antibiotic-resistant strains were more susceptible to bile acid than the wild type, and the bile acid-sensitive strains showed collateral sensitivity to an especially high number of antimicrobial peptides (Fig. 3a). To explore the common mechanistic basis of this pattern, we compared the transcriptome profiles of the wild type and 24 antibiotic-resistant strains covering all 12 investigated antibiotics (see Methods). All strains were grown in antibiotic-free medium to ensure comparability between strains that display vastly different resistance levels.

Several lines of evidence support the hypothesis that antibiotic resistance leads to alterations in outer membrane composition. In 75% of the analysed antibiotic-resistant strains, transcriptional changes are significantly enriched in LPS- and outer membrane-related genes (Fig. 3c, left panel), including genes involved in LPS biosynthesis and phospholipid binding and transfer. Importantly, strains with an especially high number of upregulated LPS-related genes (Supplementary Tables 8 and 9) display an enhanced susceptibility to bile acid (Fig. 3b). Finally, strains with upregulated genes in membrane-related functions were more likely to show collateral sensitivity to specific antimicrobial peptides (Fig. 3c and Supplementary Fig. 5).

**Chemogenomic analysis of collateral sensitivity.** To directly investigate the causality between upregulation of membrane-related genes and collateral sensitivity, we carried out a chemogenomic screen to identify genes that, when overexpressed, sensitize *E. coli* to the membrane-interacting 18-kDa cationic antimicrobial peptide (CAP18). CAP18 is an ideal choice for two reasons. First, it displaces divalent cations in the LPS layer and thereby permeabilizes the outer membrane<sup>24</sup>. Second, strains that are sensitive to CAP18 displayed upregulation of genes involved in LPS biosynthesis, and phospholipid binding and transport (Fig. 3c, Supplementary Tables 8 and 9).

The chemogenomic screen of CAP18 was carried out by applying an established plasmid collection overexpressing all *E. coli* open reading frames (ORFs)<sup>25</sup> in a pooled fitness assay with a deep sequencing readout (for details see Supplementary Fig. 6). Following growth of the pooled collection both in the presence and absence of CAP18, we identified genes that produce a growth defect when overexpressed in CAP18 treatment only (see Supplementary Fig. 6c). Such growth defects indicate increased CAP18 sensitivity upon overexpression of single genes. As a control, we performed the same assay on cecropin P1 (CP1), a peptide to which antibiotic-resistant strains rarely show collateral sensitivity (Fig. 1b). Our chemogenomic screen revealed 624 and 258 sensitizing genes for CAP18 and CP1, respectively (see Supplementary Table 10). As expected, LPS-related genes were highly enriched among genes that sensitize to CAP18, but not to CP1, when overexpressed (Supplementary Table 11). For example, LPS biosynthesis genes were especially likely to sensitize the bacteria to CAP18 when overexpressed (odds ratio = 4.4,  $P = 0.004$ , two-sided Fisher's exact test). Furthermore, CAP18-sensitizing LPS biosynthesis genes, as inferred by chemogenomics, showed higher average expression



**Table 1 | Selected individual mutations and their susceptibility profiles across antimicrobial peptides and antibiotics**

Gene	Mutation	Relative MIC change														
		P3							P2				P1			
		PGLA	HBD3	SB	IND	D28	PR39	CAP18	PROA	AP	PYR	BAC5	CEME	LL37	TPII	CP1
<i>ompC</i>	Met1lle	0.7 <sup>a</sup>	0.6 <sup>a</sup>	1.0 <sup>c</sup>	1.0 <sup>c</sup>	0.7 <sup>a</sup>	1.0 <sup>c</sup>	0.8 <sup>a</sup>	0.8 <sup>a</sup>	0.8 <sup>a</sup>	0.8 <sup>a</sup>	1.0 <sup>c</sup>	0.8 <sup>a</sup>	1.0 <sup>c</sup>	1.0 <sup>c</sup>	1.0 <sup>c</sup>
<i>trkH</i>	Thr350Lys	0.7 <sup>a</sup>	2.5 <sup>b</sup>	1.0 <sup>c</sup>	0.8 <sup>a</sup>	0.8 <sup>a</sup>	1.2 <sup>b</sup>	1.0 <sup>c</sup>	1.4 <sup>b</sup>	0.6 <sup>a</sup>	0.6 <sup>a</sup>	1.2 <sup>b</sup>	1.0 <sup>c</sup>	1.0 <sup>c</sup>	1.0 <sup>c</sup>	1.0 <sup>c</sup>
<i>sbmA</i>	Deletion	0.8 <sup>a</sup>	0.8 <sup>a</sup>	0.8 <sup>a</sup>	0.8 <sup>a</sup>	1.0 <sup>c</sup>	1.3 <sup>b</sup>	1.0 <sup>c</sup>	1.3 <sup>b</sup>	2.0 <sup>b</sup>	3.6 <sup>b</sup>	1.8 <sup>b</sup>	1.2 <sup>b</sup>	1.0 <sup>c</sup>	1.2 <sup>b</sup>	1.0 <sup>c</sup>
<i>marR</i>	Val84Glu	0.6 <sup>a</sup>	0.7 <sup>a</sup>	0.7 <sup>a</sup>	0.8 <sup>a</sup>	1.0 <sup>c</sup>	1.0 <sup>c</sup>	0.8 <sup>a</sup>	0.8 <sup>a</sup>	1.4 <sup>b</sup>	1.0 <sup>c</sup>	1.0 <sup>c</sup>	0.8 <sup>a</sup>	1.0 <sup>c</sup>	1.2 <sup>b</sup>	1.0 <sup>c</sup>
<i>waaY</i>	Overexpression	1.0 <sup>c</sup>	0.7 <sup>a</sup>	0.8 <sup>a</sup>	0.8 <sup>a</sup>	0.8 <sup>a</sup>	1.0 <sup>c</sup>	0.8 <sup>a</sup>	1.0 <sup>c</sup>	2.0 <sup>b</sup>	1.4 <sup>b</sup>	1.0 <sup>c</sup>	0.8 <sup>a</sup>	1.0 <sup>c</sup>	1.0 <sup>c</sup>	1.0 <sup>c</sup>

Gene	Mutation	Relative MIC change												
		Cell wall		Gyrase		Multiple		50 s		30 s		Folic acid	Aminoglycoside	
		AMP	FOX	CPR	NAL	NIT	CHL	ERY	DOX	TET	TRM	TOB	KAN	
<i>ompC</i>	Met1lle	>5 <sup>b</sup>	1.2 <sup>b</sup>	0.7 <sup>a</sup>	0.8 <sup>a</sup>	1.2 <sup>b</sup>	0.7 <sup>a</sup>	1.0 <sup>c</sup>	1.0 <sup>c</sup>	1.0 <sup>c</sup>	1.0 <sup>c</sup>	1.0 <sup>c</sup>	1.0 <sup>c</sup>	1.0 <sup>c</sup>
<i>trkH</i>	Thr350Lys	0.5 <sup>a</sup>	0.8 <sup>a</sup>	0.6 <sup>a</sup>	0.3 <sup>a</sup>	0.8 <sup>a</sup>	0.6 <sup>a</sup>	0.9 <sup>a</sup>	0.5 <sup>a</sup>	0.5 <sup>a</sup>	0.6 <sup>a</sup>	3.4 <sup>b</sup>	2.1 <sup>b</sup>	
<i>sbmA</i>	Deletion	1.0 <sup>c</sup>	1.0 <sup>c</sup>	1.0 <sup>c</sup>	1.0 <sup>c</sup>	1.0 <sup>c</sup>	0.7 <sup>a</sup>	1.0 <sup>c</sup>	1.2 <sup>b</sup>	1.2 <sup>b</sup>	1.0 <sup>c</sup>	1.3 <sup>b</sup>	1.5 <sup>b</sup>	
<i>marR</i>	Val84Glu	2.0 <sup>b</sup>	3.3 <sup>b</sup>	1.9 <sup>b</sup>	2.1 <sup>b</sup>	1.0 <sup>c</sup>	2.2 <sup>b</sup>	2.0 <sup>b</sup>	1.9 <sup>b</sup>	1.8 <sup>b</sup>	1.3 <sup>b</sup>	1.0 <sup>c</sup>	1.0 <sup>c</sup>	
<i>waaY</i>	Overexpression	1.4 <sup>b</sup>	1.0 <sup>c</sup>	1.2 <sup>b</sup>	1.2 <sup>b</sup>	0.5 <sup>a</sup>	NA	1.2 <sup>b</sup>	1.0 <sup>c</sup>	1.0 <sup>c</sup>	1.4 <sup>b</sup>	1.7 <sup>b</sup>	2.0 <sup>b</sup>	

The selected mutations repeatedly occurred in different antibiotic-resistant strains. Each mutation was inserted back into the wild-type strain separately. Relative change in MIC was calculated as the ratio between the MIC of the compound on the mutant strain and on the wild-type strain. Values lower, higher and equal to one represent <sup>a</sup>collateral sensitivity, <sup>b</sup>cross-resistance or <sup>c</sup>no interaction, respectively. Data on antibiotic susceptibility are based on results previously published in case of the *envZ*, *marR* and *trkH* mutants<sup>2</sup>. NA, not available. For antibiotic and antimicrobial peptide abbreviations, see Supplementary Tables 1 and 2.

levels in those antibiotic-resistant strains that are sensitive to CAP18 compared to the rest ( $P=0.008$ , two-sided Wilcoxon rank-sum test, Fig. 3d). We note that, although also frequently upregulated in CAP18-sensitive strains (Fig. 3c), genes with phospholipid-related functions were not enriched among sensitizing genes in the chemogenomic screen (Supplementary Table 11). Taken together, these analyses indicate that altered LPS biosynthesis plays a causal role in the widespread collateral sensitivity of antibiotic-resistant strains to antimicrobial peptides.

**A *marR* mutation induces collateral sensitivity.** We next deciphered a mechanistic link between a specific regulatory mutation and its impact on antibiotic resistance and collateral sensitivity. We focused on *marR*, as mutation in this gene affects bacterial response to antimicrobials in two opposite ways: it increases resistance to multiple antibiotics, but simultaneously sensitizes to membrane-interacting peptides (Table 1). Why is this so?

LPS is a major component of the bacterial outer membrane that stabilizes the membrane structure, regulates its permeability and contributes to its negative charge<sup>26</sup>. The *mar* regulon is known to mediate LPS modification by positively regulating *WaaY*, a kinase responsible for phosphorylation of the inner core of LPS, leading to an increased negative surface charge of the bacterial outer membrane<sup>27,28</sup> (Fig. 4). As an increased negative surface charge of the membrane generally promotes antimicrobial peptide killing efficiency<sup>9,27</sup>, upregulation of *waaY* is expected to enhance bacterial susceptibility to peptides.


Based on these facts, we hypothesized that mutations in *marR* increase antimicrobial peptide susceptibility through upregulation of *waaY*. Such upregulation should lead to an increase in phosphorylation of LPS and, as a consequence, elevated negative surface charge of the bacterial outer membrane (Fig. 4). Several lines of evidence support this hypothesis. First, the antimicrobial peptide susceptibility profiles of the *marR* single-mutant and the *waaY*-overexpressing strain showed substantial overlap (Table 1). Second, gene expression analysis using reverse-transcription quantitative PCR (RT-qPCR)

confirmed that *waaY* is nearly fourfold upregulated in the *marR* single-mutant strain when compared to the wild type (fold change:  $3.88 \pm 0.026$  s.e.m., see Methods). Third, we carried out zeta potential measurements and demonstrated that both the *marR* mutant and the *waaY*-overexpressing strain display relatively high negative surface charge compared to the wild type (Supplementary Fig. 7). Finally, inactivation of *waaY* abolished collateral sensitivity to P3 peptides in *marR* mutants (Supplementary Fig. 8). To summarize, these results indicate that collateral sensitivity of the *marR* mutant to peptides occurs via modulation of the LPS phosphorylation pathway. We propose that the consequent altered outer membrane composition facilitates the interaction of antimicrobial peptides with the cell membrane and thereby enhances their killing efficiency (Fig. 4).

**Peptide PGLA restores antibiotic activity in antibiotic-resistant bacteria.** The above results have important implications for future development of drug combinations. Recently, two complementary mechanisms were proposed to contribute to the selective eradication of drug-resistant bacteria<sup>29</sup>. First, resistance to one drug can induce hypersensitivity to the other (collateral sensitivity, see also Supplementary Text 4)<sup>1,2</sup> and, second, interactions can become more synergistic with the evolution of resistance, making the mutant more sensitive to the combination (resistance mutation-induced synergy)<sup>30</sup>.

We focused on PGLA for two reasons. First, it shows an exceptionally high number of collateral sensitivity interactions (Fig. 1). Second, when used in combination, antibiotic-PGLA pairs show strong synergism in antibiotic-resistant, but not in the corresponding wild-type, bacteria (Fig. 5a–d, Supplementary Table 12). Remarkably, strong synergism is prevalent in antibiotic-resistant strains carrying mutations in *marR*, *envZ* or *ompF*. As these genes influence membrane permeability, we speculate that PGLA may interfere with the activity of multidrug efflux systems and/or porins responsible for the observed antibiotic resistance in these strains.

We then tested whether PGLA could be used as an adjuvant and selectively potentiate antibiotic activity against antibiotic-resistant




**Fig. 3 | Altered membrane composition in antibiotic-resistant bacteria contributes to increased sensitivity to antimicrobial peptides.** **a**, Antibiotic-resistant strains sensitive towards a membrane-damaging agent (bile acid) show especially large numbers of collateral sensitivity interactions with antimicrobial peptides. For antibiotic abbreviations see Supplementary Table 1. Strains sensitive to bile acid show significantly more collateral sensitivity interactions to peptides than those showing wild-type bile acid sensitivity (not sensitive group) ( $P < 10^{-3}$ , two-sided GLMM with binomial response distributions, see Methods section). Relative frequency was calculated by dividing the number of the collateral sensitivity interactions by the number of all tested peptides ( $N = 24$ ). **b**, Resistant strains with sensitivity to bile acid have significantly more LPS-related synthesis genes being transcriptionally upregulated than those showing wild-type bile acid sensitivity ( $P < 10^{-3}$ , two-sided GLMM with binomial response distributions). Relative frequency was calculated by dividing the number of upregulated genes by the number of all LPS-related genes ( $N = 100$ ). **c**, Left heatmap shows the average log<sub>2</sub>(fold change (FC)) of genes related to selected membrane-associated gene ontology processes. Many antibiotic-resistant strains are enriched in significantly up- or downregulated genes (fold change  $> 2$  or  $< 0.5$ , false discovery rate (FDR)-corrected  $P$ -value  $< 0.05$ , two-sided Fisher's exact test) associated with membrane-related functions. Significant enrichments ( $P < 0.05$ ) are marked with an asterisk (\*). Strains sensitive to a given peptide show significant upregulations in specific gene ontology groups compared to non-sensitive strains (right heatmap, two-sided Student's  $t$ -test; for further details, see Supplementary Fig. 5). Peptides with either too few or too many collateral sensitivity interactions ( $n < 4$  or  $n > 21$ , respectively) were excluded from the statistical analysis based on sample size calculation with  $\alpha = 0.1$ , power = 0.8,  $\delta = 2$ , s.d. = 1, and are indicated with a minus sign (–). Sample size used in this analysis is provided in Supplementary Table 3. **d**, Upregulation of LPS-related genes sensitizes to CAP18. CAP18-sensitive antibiotic-resistant strains (CS,  $n = 12$ ) have significantly higher expression levels of CAP18-sensitizing genes within the 'LPS biosynthetic process' gene ontology category than non-sensitive strains (not CS,  $n = 12$ ) ( $P = 0.008$ , two-sided Wilcoxon rank-sum test). Boxplots show the median, first and third quartiles, with whiskers showing the 5th and 95th percentile. Significant differences are marked with asterisks (\*\* $P < 0.01$  and \*\*\* $P < 0.001$ ).

bacteria. We tested CPR-, NAL-, tetracycline (TET)- and doxycycline (DOX)-resistant *E. coli*, including laboratory-evolved strains (Fig. 5e–g) and clinical isolates (Fig. 5h–j, Supplementary Fig. 9). The dataset was also augmented with NAL-resistant *Klebsiella pneumoniae* and *Shigella flexneri* isolates (Supplementary Fig. 10). PGLA was administered at subinhibitory concentrations; that is, it allowed growth of the wild-type and the antibiotic-resistant strains alike. Strikingly, when used in combination, PGLA caused up to 30-fold decrease in the antibiotic resistance level of the resistant strains (Fig. 5e–g, Supplementary Figs. 9 and 10, and Supplementary Table 13). We conclude that PGLA can restore antibiotic susceptibility against resistant bacteria when administered as an adjuvant.

**PGLA inhibits de novo evolution of resistance to antibiotics.** Finally, we asked whether concurrent administration of antibiotics

with subinhibitory dosages of PGLA hinders de novo resistance evolution in the laboratory (Fig. 6). To this end, we focused on two antibiotic-peptide combinations, CPR-PGLA and TET-PGLA. We evolved the wild-type *E. coli* strain in the presence of these antibiotic-PGLA combinations and their corresponding single drug components. The protocol aimed to maximize the level of antibiotic resistance in the evolving populations during a fixed time period. For each of the eight drug conditions, ten parallel bacterial lineages were evolved (Methods).

After only 160 generations, bacterial populations evolving in the presence of a single antibiotic reached 40- and 390-fold increases in TET and CPR MIC levels relative to their ancestor, respectively (Fig. 6a,b). Reassuringly, collateral sensitivity to PGLA arose in these lineages (Fig. 6d,e). In contrast, antibiotic-PGLA co-treatment significantly slowed down the evolution of antibiotic resistance. In the presence of subinhibitory dosages of PGLA, the level of



**Fig. 4 | A putative mechanism underlying collateral sensitivity of antibiotic-resistant bacteria to cationic antimicrobial peptides. a**, The wild-type MarR represses *marA*, which leads to the reduced expression of the AcrAB-TolC efflux pump and hence the cytosolic accumulation of antibiotics. **b**, Upon a canonical resistance mutation in the *marR* gene (*marR\**), repression of *marA* is substantially decreased leading to the upregulation of the AcrAB-TolC efflux pump, and hence an increased resistance to multiple antibiotics. On the other hand, MarA simultaneously promotes the upregulation of WaaY, a kinase responsible for phosphorylation of the inner core of LPS, which increases the net negative surface charge of the bacterial outer membrane. This in turn enhances susceptibility to membrane-interacting cationic antimicrobial peptides (+). In addition, phosphorylation of the LPS core may also enhance the permeability barrier of the outer membrane by cross-linking of neighbouring LPS molecules. Such changes promote both (1) a decreased uptake and increased efflux of antibiotics, thereby contributing to antibiotic resistance, and (2) a higher affinity of the positively charged antimicrobial peptides to the negative phosphoryl groups (P<sup>-</sup>) of the LPS core, leading to enhanced sensitivity to antimicrobial peptides.

antibiotic resistance reached during the course of laboratory evolution was tenfold lower than in the absence of PGLA, and it remained consistently below the suggested EUCAST clinical breakpoints (Fig. 6a,b). In addition, evolution of resistance to PGLA was marginal (Fig. 6d,e). Reassuringly, no substantial cross-resistance was observed between PGLA and the antibiotics CPR or TET (Fig. 6). These patterns are not due to variations in population size across treatments (Supplementary Fig. 11).

We suspect that the efficiency of the antibiotic-PGLA co-treatment reflects an elevated fitness cost of antibiotic resistance mutations under such conditions. In other words, collateral sensitivity to PGLA may reduce the number of available resistance-conferring mutations under CPR-PGLA or TET-PGLA co-treatment (see also Supplementary Fig. 12). A full answer to this question will require detailed molecular and phenotypic characterization of laboratory-evolved bacteria. As a preliminary test, we used the drug pair TOB-bactenecin 5 (BAC5), as TOB-resistant strains showed cross-resistance rather than collateral sensitivity to the peptide BAC5 (Fig. 1). As expected, the TOB-BAC5 combination did not reduce the rate of antibiotic resistance evolution (Fig. 6c,f).

## Discussion


How do mutations conferring antibiotic resistance change the susceptibility to antimicrobial peptides? This question is all the more relevant as antimicrobial peptides are promising antibacterial alternatives to antibiotics currently used in the clinics<sup>8,9</sup>. In this work, we applied an integrated approach to study the susceptibilities of antibiotic-resistant *E. coli* strains towards antimicrobial peptides.

First, we found that antibiotic-resistant bacteria generally exhibited collateral sensitivity (increased susceptibility) to antimicrobial peptides, while cross-resistance was relatively rare. Several prior works have investigated cross-resistance and collateral sensitivity interactions between conventional antibiotics<sup>1–3,31,32</sup>. Despite substantial

differences in the protocols, these systematic studies agreed that cross-resistance is generally 2–3 times more frequent than collateral sensitivity. By contrast, we see nearly three times more collateral sensitivity than cross-resistance towards antimicrobial peptides (Fig. 1).

Second, although we studied bacteria adapted to a diverse set of antibiotics with major differences in their mechanisms of action (Supplementary Table 1), bacterial susceptibilities to antimicrobial peptides revealed several general trends. This is partly due to mutations in canonical resistance genes that emerged repeatedly in response to various antibiotic stresses. By introducing these mutations into a wild-type genetic background, we showed that mutations conferring resistance to one or more antibiotics simultaneously increase sensitivity to several antimicrobial peptides (Table 1). The most noteworthy example is the transcriptional repressor of the *mar* regulon (*marR*). Mutations in this gene are frequently observed both in the laboratory and in clinical settings, and increase resistance to multiple unrelated antibiotics<sup>2,22</sup>. Here, we showed that a mutation in this gene increases the negative surface charge of the bacterial outer membrane (Supplementary Fig. 7) and, eventually, leads to elevated susceptibility to several antimicrobial peptides.

More generally, our findings indicate that susceptibility to antimicrobial peptides arises as a by-product of genomic expression changes in antibiotic-resistant bacteria (Fig. 3), presumably because these alterations modify the chemical structure of the bacterial outer membrane. Importantly, these conclusions do not hold for all combinations of antimicrobial peptides and resistant bacteria studied. Most notably, aminoglycoside-resistant bacteria accumulated a distinct set of mutations showing practically no overlap with other laboratory-evolved antibiotic-resistant bacteria<sup>2</sup>. They uniquely carried deleterious mutations in the gene encoding the inner membrane transport protein *sbmA*<sup>2,3</sup>. This mutation delivered resistance to proline-rich peptides and aminoglycosides as well (Fig. 1 and Table 1).




**Fig. 5 | Interaction of PGLA and antibiotics when applied in combination.** Antibiotic–PGLA interactions were determined in *E. coli* K-12 BW25133 wild-type and corresponding antibiotic-resistant strains. For antibiotic abbreviations see Supplementary Table 1. **a–d**, The combination effect of PGLA and CPR or TET on the wild-type strain (**a** and **c**), CPR-resistant strain (CPR7) (**b**) and TET-resistant strain (TET3) (**d**). While the combination shows strong antagonism (**a**) or no interaction (**c**) in the wild-type strain, the interaction shifted to strong synergism in the resistant strain (**b** and **d**). Dashed line represents no interaction calculated based on the Loewe additivity model (see Methods). Growth rate is represented in the combination space by the shade of the grey colour with darker shades denoting higher growth rates. **e–j**, The effect of subinhibitory concentrations of PGLA on antibiotic activity. CPR-resistant CPR7 (**e**), TET-resistant TET3 (**f**) and DOX-resistant DOX3 (**g**) strains, derived from *E. coli* K-12 BW25133, were treated with subinhibitory concentrations of PGLA, while measuring the MIC for the given antibiotic to which they were adapted. The concentrations of PGLA used were 1/16, 1/8, 1/4 and 1/2 of its MIC against the wild-type strain. The MIC of NAL was measured in *E. coli* clinical isolates O370 (**h**), 3539 (**i**) and CFT073 (**j**), and their corresponding NAL-resistant strains in the presence of 1/2 of the MIC for PGLA. None of the PGLA concentrations, when applied alone, affected the growth of the wild-type or the resistant strains (the only exception being the 40% growth rate reduction of the TET-resistant strain in response to 1/2 MIC PGLA). Dashed lines represent the clinical breakpoints for the antibiotics in *E. coli* (not available for DOX). Data in this figure are representative of at least two biological replicates. CI, combination index.

These considerations could be important for the development of combination therapies. The fact that antibiotic-resistant strains showed extensive collateral sensitivity to certain antimicrobial peptides led us to study one of them, PGLA, in more detail. We identified two important properties of PGLA. First, antibiotic resistance generally resulted in collateral sensitivity to this peptide (Fig. 1) and, second, antibiotic–PGLA combinations induced synergism in certain antibiotic-resistant bacteria (resistance mutation-induced synergy, Fig. 5a–d). Based on these properties, we hypothesized that PGLA could be used for the eradication of drug-resistant bacteria as well as the inhibition of de novo resistance evolution. When used in combination, a subinhibitory dose of

PGLA caused up to 30-fold increase in susceptibility in antibiotic-resistant bacteria (Fig. 5e–j). Furthermore, co-administration of the same subinhibitory dose of PGLA efficiently slowed down the evolution of antibiotic resistance and kept resistance levels under the EUCAST breakpoints (Fig. 6). Future works should examine whether such a combination strategy can be maintained over longer time scales without the appearance of resistance mutations that diminish the antibiotic–PGLA synergy<sup>33</sup>. Needless to say, we only consider PGLA as a first step towards the development of an adjuvant therapy. By studying the structural and functional properties of promising antimicrobial peptides, peptidomimetic molecules could be developed that are less prone to resistance, stable against





**Fig. 6 | MICs of laboratory-evolved lines adapted to antibiotics in the absence and the presence of subinhibitory dosage of antimicrobial peptides.**

**a–f**, MIC was measured following a laboratory evolution of the wild-type *E. coli* strain to TET (green), CPR (blue) and TOB (orange) in the absence or in the presence of 1/4 or 1/2 of the MIC of the antimicrobial peptides PGLA (**a, b, d, e**) or BAC5 (**c, f**) against the wild-type strain. MICs of the wild type and both PGLA and BAC5 evolved lines (in the absence of antibiotic) are represented by grey and white coloured bars, respectively. Each data point represents the MIC value of one of each ten parallel-evolved lines. Error bars represent the mean  $\pm$  s.e.m. for each experimental condition. Dashed lines represent clinical breakpoints for TET, CPR or TOB in *E. coli*. Both the CPR-PGLA and the TET-PGLA combinations, which are representatives of collateral-sensitive interactions (Fig. 1), significantly slowed down the evolution of resistance towards the given antibiotic when administered together. Reassuringly, the control combination (BAC5-TOB), representing a cross-resistance interaction, did not reduce the rate of TOB resistance evolution ( $P=0.0834$ , one-way analysis of variance).

human proteases<sup>8,34</sup> and efficient against a broad range of drug-resistant pathogens.

An important unresolved issue is whether collateral-sensitive peptide-antibiotic combinations could also be employed sequentially to select against resistance. This strategy, termed collateral sensitivity cycling, has remained controversial<sup>1,35</sup>. Our preliminary results indicate that the two key ingredients of this strategy are present. First, evolving resistance to an antimicrobial peptide (CAP18) results in collateral sensitivity to several conventional antibiotics, and this collateral sensitivity is reciprocal (Supplementary Fig. 13). Second, both antibiotic- and CAP18-resistant bacteria can be selectively eradicated by deploying the collateral-sensitive drug partner (Supplementary Fig. 14).

Last, we need to emphasize the limitations of our work. The molecular mechanisms underlying collateral sensitivity need to be addressed in more detail. It also remains to be established whether antimicrobial peptide-antibiotic combinations generally outperform conventional antibiotic combinations in their ability to hinder resistance evolution. At best, we made the first step in these directions. An important objection to clinical usage of antimicrobial peptides is that acquisition of resistance against synthetic antimicrobial peptides could drive cross-resistance towards antimicrobial peptides of the host innate immune system<sup>36,37</sup>. While this is certainly a realistic danger—at least in laboratory settings—two notes must be made. First, the diverse susceptibility profiles of antibiotic-resistant strains towards antimicrobial peptides (Fig. 1) confirm major differences both in the mechanisms of action of antimicrobial peptides and the potential routes to antimicrobial peptide resistance. Second, our data indicate that certain peptide-antibiotic combinations could select against the de novo evolution of resistance against both agents (Fig. 6).

In summary, our work establishes that antibiotic-resistant bacteria frequently show collateral sensitivity to antimicrobial peptides, a finding that can be utilized to identify peptide-antibiotic combinations that effectively eradicate resistant bacteria and slow down the de novo evolution of resistance to antibiotics.

## Methods

**Medium, antimicrobial agents and strains used in the study.** *Antimicrobial peptides.* Twenty-four cationic antimicrobial peptides were used in this study: SB006, HBD3, PROA, PR-39, PGLA, pexiganan (PEX), indolicidin (IND), BAC5 and bactenecin 7 (BAC7), NCR335, magainin 2 (MAG), R8, D28, anginex (ANG), apidaecin IB, rabbit CAP18, pyrrolicocricin (PYR), pleurocidin (PLEU), synthetic cecropin-melittin hybrid (CEME), protegrin-1 (PRO1), polymyxin B (PXB), LL37, tachyplesin II (TPII) and CP1 (see also Supplementary Table 2). Antimicrobial peptides were custom synthesized by ProteoGenix, except for PROA and PXB, which were purchased from Sigma-Aldrich. The antimicrobial peptide solutions were prepared in sterile water and kept at  $-80^{\circ}\text{C}$  until usage.

*Antibiotics.* The following antibiotics were used in this study (see also Supplementary Table 1): chloramphenicol (CHL), TET, AMP, FOX, CPR, erythromycin (ERY), DOX, trimethoprim (TRM), TOB, KAN, NIT and NAL. Most of the antibiotics were purchased from Sigma-Aldrich, except for ERY (AMRESCO) and DOX (AppliChem). Fresh antibiotic solutions were prepared from powder stocks on a weekly basis, kept at  $-20^{\circ}\text{C}$  and filter sterilized before use.

*Strains.* *E. coli* K-12 BW25113 was used as the wild-type strain. The 60 laboratory-evolved resistant strains, adapted to 12 different clinically relevant antibiotics (5 evolved lines per antibiotic with the exception of AMP and NAL, for which 4 and 6 replicates were used, respectively) were established in our previous work<sup>1</sup>. Briefly, the parallel-evolved populations reached up to 328-fold increases in the MICs relative to the ancestor. In all cases, the resistance levels were equal to or above the current clinical breakpoints according to EUCAST or the European Reference Laboratory for Antimicrobial Resistance. The evolution of multidrug resistance (resistance to two or more drugs) was frequent under a single antibiotic pressure: on average, 52% of all investigated antibiotic pairs showed cross-resistance in

at least one direction. Parallel-evolved lines were subjected to whole-genome sequencing to characterize the mutations responsible for multidrug resistance. On average, we detected 4.2 point mutations, 1.2 deletions, 0.26 insertions and 0.07 duplications per clone. Details of the laboratory evolution experiments as well as the results of the whole-genome sequencing of the evolved strains are available in our previous works<sup>2,3</sup>.

The four *E. coli* single-mutant strains (envZ[Ala396Thr], ompC[Met1Ile], marR[Val84Glu], trkH[Thr350Lys]) were established using a highly precise allele replacement protocol described in our previous studies<sup>2,3,38</sup>. The *sbmA* single-gene deletion mutant was derived from the KEIO collection<sup>39</sup>. Both the wild-type and ompC[Met1Ile] strains were transformed with the *waaY* overexpression and the empty plasmids isolated from the ASKA (A complete set of *E. coli* K-12 Open Reading Frame Archive library) collection<sup>25</sup>.

The three *E. coli* uropathogen clinical isolates (0370, 3538, CFT073) before and after adaptation to three different antibiotics (gentamicin (GEN), NAL and AMP), the *K. pneumoniae* r1 (A) and the *S. flexneri* 668 clinical isolates and their NAL-evolved strains were kindly provided by Morten Sommer, Technical University of Denmark, Horsholm. Four CPR-resistant *E. coli* isolates, 1 to 4, were obtained from the local hospital and kindly provided by Edit Urbán, Department of Clinical Microbiology, University of Szeged, Hungary. Strains 1 to 3 were isolated from urine samples, while strain 4 was isolated from intraperitoneal puncture. *E. coli* ATCC 25922, BAA 2469 and BAA 2340 strains were obtained from Microbiologics.

**Medium.** In line with previous, methodologically relevant laboratory evolution studies<sup>31,32,40</sup>, the physical conditions (including the medium) were the same during the course of laboratory evolution and all forthcoming assays on the resulting resistant lines. The logic is to minimize any potential confounding effects unrelated to adaptation to the antibiotic studied (that is, the only difference being the presence/absence of a given drug). Therefore, as a general rule, the same chemically defined medium and growth conditions were employed throughout the experiments in which the investigated antibiotic-resistant strains were evolved. This medium was optimized for a large set of antimicrobial peptides by decreasing the sodium citrate and the magnesium sulfate concentrations. This optimized medium was minimal salts medium (1 g l<sup>-1</sup> (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 3 g l<sup>-1</sup> KH<sub>2</sub>PO<sub>4</sub> and 7 g l<sup>-1</sup> K<sub>2</sub>HPO<sub>4</sub>) supplemented with 0.1 mM MgSO<sub>4</sub>, 0.54 µg ml<sup>-1</sup> FeCl<sub>3</sub>, 1 µg ml<sup>-1</sup> thiamine hydrochloride, 0.2% Cas amino acids and 0.2% glucose. Phosphate was available in the medium. This is important as scarcity of phosphate can modify the membrane composition and therefore the activity of antimicrobial peptides<sup>41,42</sup>. Unlike Muller–Hinton broth, the minimal salts medium used in our work is a chemically defined, highly controlled and reproducible environment, a characteristic that is particularly important in laboratory evolution and high-throughput screenings. As an exception, note that Muller–Hinton II medium was used to study drug susceptibility of *S. flexneri* 668 strain, as this strain cannot grow in minimal salts medium. Reassuringly, the applied medium did not have an effect on the activity of PGLA when used as an adjuvant (see Supplementary Fig. 10 where experiments with *K. pneumoniae* were done in minimal salts medium while the ones using *S. flexneri* were performed in Muller–Hinton II medium). All components were obtained from Sigma–Aldrich.

**Systematic measurement of antimicrobial peptide susceptibilities.** We aimed at detecting changes in the sensitivities of a large number of antibiotic-resistant strains compared to the wild-type strain towards a wide variety of antimicrobial peptides as well as bile acid. To this end, we developed a high-throughput screening and a robust statistical analysis methodology for the systematic detection of cross-resistance and collateral sensitivity interactions in *E. coli*. We compared the susceptibility of 60 antibiotic-resistant strains (5 evolved lines per antibiotic, established in our previous work<sup>2</sup>) to the wild-type strain across the entire set of antimicrobial peptides ( $n=24$ ) and bile acid (Fig. 1 and Supplementary Table 3). The three main steps of our methodology were (1) high-throughput measurement of growth inhibition of strains in liquid cultures in 96-well microtiter plates with the aim of detecting collateral-sensitive and cross-resistant phenotypes without precise MIC measurements (see below); (2) validation of the high-throughput results by standard MIC measurements on a subset of strain-peptide condition pairs and using receiver operating characteristic (ROC) curve analysis; (3) further validation of collateral sensitivity interactions at high antimicrobial peptide dosages using kill curve assays.

**High-throughput estimation of collateral sensitivity and cross-resistance.** To infer collateral sensitivity and cross-resistance interactions, we compared the growth sensitivity of antibiotic-resistant and wild-type strains by measuring their propensity to be arrested in growth by two specific dosages. In this screen, approximately 10<sup>8</sup> bacteria per ml were inoculated into each well of the 96-well microtiter plate with a 96-pin replicator, and were propagated at 30°C with shaking at 300 r.p.m. Bacterial growth was monitored by measuring absorbance 600 nm ( $A_{600\text{nm}}$ ) of the liquid cultures at a single time point after 24 h of incubation in the presence of a given antimicrobial peptide. Growth arrest was defined as the failure to obtain growth at a given peptide concentration (that is,  $A_{600\text{nm}}$  was below the mean + 2 s.d. of  $A_{600\text{nm}}$  values of bacteria-free wells containing only growth medium). In order to be able to discern condition-specific growth arrest from

slow growth caused by a general cost of resistance, we chose an incubation time of 24 hours where all populations reached detectable growth in medium devoid of antimicrobial peptide. In order to maximize reproducibility and accuracy, a robotic liquid-handling system and an automatic incubator were used.

Antibiotic-resistant strains and wild-type strain were inoculated in 4 and 12 replicate populations on the same 96-well plate, respectively. Growth arrest was determined for each of them and an inhibition score was calculated based on the replicate measurements as follows: Inhibition score = (NGA<sub>control</sub>/12) - (NGA<sub>ABstrain</sub>/4). NGA is the number of replicates showing growth arrest out of the 12 control populations (NGA<sub>control</sub>) or out of the 4 antibiotic-resistant populations (NGA<sub>ABstrain</sub>). Two different peptide concentrations were chosen as one above (~1.2×) and one below (~0.8×) the MIC of the wild-type strain. The lower and the higher concentrations were applied to calculate inhibition score for collateral sensitivity and cross-resistance interactions, respectively. Specifically, to detect collateral sensitivity against a given peptide, we tested whether a peptide dosage below the wild-type MIC (0.8×) fully inhibits growth of a particular antibiotic-resistant strain, but not the wild-type. To detect cross-resistance, we applied a peptide dosage somewhat above the wild-type MIC (1.2×), and asked whether antibiotic-resistant strains can grow. We conducted at least four independent experimental runs for each combination of strains and peptide conditions. Next, to filter out unreliable measurements for the detection of cross-resistance/collateral sensitivity interactions, we excluded cases where (1) cross-contamination might have occurred on the plate during susceptibility measurements (based on growth in non-inoculated wells), (2) the control wells devoid of peptide showed large variations (coefficient of variation was above 20%), (3) in the case of collateral sensitivity interactions where the applied dosages were too high and arrested the growth of more than 50% of the control populations and (4) in the case of cross-resistance interactions where the applied dosages were too low and only arrested the growth of less than 50% of the control populations. This quality control procedure resulted in 2–4 replicates for each combination of strains and peptide conditions. Then, we calculated the average of the inhibition score derived from the multiple independent experimental runs, and defined cut-off values of the inhibition score to detect cross-resistance and collateral sensitivity interactions, respectively (see below).

To define a robust cut-off value on the inhibition score, we first performed a detailed analysis of MIC on a subset of strain-peptide condition pairs ( $n=110$ ) (Supplementary Table 4). Each antibiotic-resistant strain was characterized as to show cross-resistance or collateral sensitivity to a certain antimicrobial peptide if it showed at least 20% difference in its MIC value compared to the wild-type strain. Next, we chose an inhibition score threshold that maximized the fit between the results of the high-throughput susceptibility screen and those of the traditional MIC measurements. The fit between the two datasets was defined as the area under the ROC curve calculated from the inhibition score of the high-throughput susceptibility screen and the collateral sensitivity/cross-resistance classification of the detailed MIC measurements. The area under the ROC curve (AUC) is a measure of how well the inhibition score can distinguish between cross-resistance/collateral sensitivity interactions and the absence of interactions. The calculated AUC was 0.89 and 0.93 for the collateral sensitivity and cross-resistance interactions, respectively. A random classifier has an AUC of 0.5, while AUC for a perfect classifier is equal to 1. The cut-off point of the inhibition score was chosen as the value that minimizes the Euclidean distance between the ROC curve and the optimum point of the graph (true positive rate = 1, false positive rate = 0).

**MIC measurements.** MICs were determined using a standard serial broth dilution technique<sup>43</sup>. In order to maximize reproducibility and accuracy, we used a robotic liquid-handling system to prepare 12-step serial dilutions automatically in 96-well microtiter plates. In case of determination of relative MIC involving the measurement of small changes, 1.15–1.5-times dilutions were used, and approximately 10<sup>8</sup> bacteria per ml were inoculated into each well using a 96-pin replicator and were propagated at 30°C with shaking at 300 r.p.m. (3 replicates per strain per antimicrobial peptide concentration). This protocol was previously established with the aim of identifying small changes in relative MICs in a high-throughput and reproducible manner<sup>2,5</sup>. Otherwise, experiments on the impact of PGLA co-treatment of antibiotic-resistant levels or determination of antibiotic and peptide MIC levels upon evolution of resistance used 2-times dilutions and an inoculum of 5 × 10<sup>5</sup> bacteria per ml as suggested by the Clinical and Laboratory Standards Institute (CLSI) guidelines. To avoid possible edge effects, rows A and H contained only media devoid of cells. The environment during incubation was also set to minimize evaporation and hence edge effects. After 24 h of incubation at 30°C, raw  $A_{600\text{nm}}$  values were measured in a Biotek Synergy microplate reader. MIC was defined by a cutoff  $A_{600\text{nm}}$  value (mean + 2 s.d. of  $A_{600\text{nm}}$  values of bacteria-free wells containing only growth medium). Relative MIC was calculated as follows:  $MIC_{\text{relative}} = MIC_{\text{ABresistant}} / MIC_{\text{control}}$ .

**Kill curve assay.** Tolerance of antibiotic-resistant strains to antimicrobial peptides was measured by determining changes in population size upon exposure to lethal concentrations of PGLA (15×MIC), PROA (15×MIC), IND (10×MIC) in the wild-type, various antibiotic-resistant and single-mutant strains. The experiments were conducted in 96-deep well plates (1,000 µl medium supplemented with the

peptide). Each well initially contained approximately  $10^6$  cells. During antibiotic treatment, three samples were taken at multiple time points (0, 15, 30, 60, 90 and 120 minutes postexposure) from each three parallel populations per strain. The total number of viable cells (colony forming units) was estimated from colony counts after plating the diluted cells on agar plates and incubating them for 24 hours.

**Membrane integrity measurements.** Membrane integrity of the antibiotic-resistant strains was investigated by measuring their sensitivity to the amphipathic LPS and outer membrane-related genes-damaging agent bile acid (see Methods: High-throughput estimation of collateral sensitivity and cross-resistance). Antibiotic-resistant strains were then grouped by their sensitivity to bile acid: sensitive strains could not grow on medium supplemented with 6% bile acid while non-sensitive strains were able to grow on this concentration. We compared the number of antibiotic-resistant strains that showed collateral sensitivity to antimicrobial peptides between the above two groups (Fig. 3a). Because the number of antibiotic-resistant strains qualifies as count data, we assessed statistical significance in this comparison using a generalized linear mixed model (GLMM) with binomial response distributions and logit link functions as implemented in the R package 'lme4'<sup>44</sup>. We note that the variable representing the number of antibiotic-resistant strains was set as an observational-level random effect to account for overdispersion<sup>45</sup>.

**Total RNA isolation.** Total RNA was extracted, as described previously<sup>46</sup>, from samples grown in minimal medium devoid of any antibiotic to ensure comparability of strains that show vastly different resistance levels across antibiotics. Samples were collected in log-phase growth ( $A_{600\text{nm}} \approx 0.5$  for RT-PCR experiments and  $A_{600\text{nm}} \approx 1$  for RNA sequencing) applying the QIAGEN RNA Protect bacteria reagent and stored at  $-80^\circ\text{C}$  until RNA isolation. RNA isolation was performed using NucleoSpin RNA extraction kit (Macherey-Nagel) according to the manufacturer's protocol. Purity of total RNA was determined as 260 nm/280 nm absorbance ratio with expected value of 2.0 by the NanoDrop 1000 spectrophotometer (Thermo Scientific). RNA integrity was confirmed by gel electrophoresis using 1% agarose with GelRed staining. Total RNA was DNase I treated by Ambion DNase I to eliminate residual genomic DNA.

**Whole transcriptome sequencing and data analysis.** Whole transcriptome sequencing was performed on 24 antibiotic-resistant strains (2 strains per antibiotic, 3 biological replicates per strain) as described previously<sup>47</sup>. The reference genome sequence (U00096.3) as well as genome annotation data were downloaded from the EcoGene 3.0 database (<http://www.ecogene.org/>)<sup>48</sup> for *E. coli* strain K-12 MG1655. Raw sequence data were size-selected by discarding reads shorter than 50 base pairs (bp). This filtering was applied to ensure maximum read quality and consistent read mapping parameters. CLC Genomic Workbench tool version 7.5.1 (CLC Bio now part of Qiagen) was used to obtain gene expression estimates (mapped read counts) for each annotated gene in all samples using the following CLC RNA-Seq analysis parameters: the maximum number of mismatches was set to 2 with minimum length and similarity fractions both set to 0.8 and unambiguous match hit set to 10. It is important to note that the applied alignment length parameter is expressed as a fraction of the raw read length. This could result in a more permissive mapping for shorter reads. In order to ensure the same mapping stringency for all reads, we decided to exclude reads shorter than 50 bp. Please also note that the excluded short raw read fraction is generated by the SOLiD analysis pipeline due to the removal of low quality read parts. SOLiD low quality readouts, as well as the resulting short reads, are expected to appear randomly within the sequencing run. That way, the removal of reads shorter than 50 bp is not expected to cause any bias in the subsequent differential gene expression analysis. Read count data were then imported into R version 3.0.2<sup>49</sup> excluding ribosomal DNA (rDNA) genes. Genes were filtered based on their expression levels, keeping only those features that were detected by at least five mapped reads in at least 25% of the samples included in the study. Subsequently, 'calcNormFactors' from package 'edgeR' version 3.4.2<sup>50</sup> was used to perform data normalization based on the 'trimmed mean of M-values' method<sup>51</sup>. Log transformation and quantile normalization was carried out by the 'voom' function of the 'limma' package version 3.18.1<sup>52</sup>. 'ComBat' tool from the 'sva' package version 3.8.0<sup>53</sup> was applied to correct for systematic batch effects that were caused by growing subsets of the samples in separate batches. Linear modelling, empirical Bayes moderation and calculation of differentially expressed genes were carried out using 'limma'.

The selection of differentially expressed genes was based on the comparison of the normalized counts per read of the control and the antibiotic-resistant strains. Genes with significant differences (false-discovery rate corrected  $P$  values  $< 0.05$ ) and with fold change (FC) greater than a chosen threshold ( $|\log_2(\text{FC})| > 1$ ) were regarded as differentially expressed. The  $\log_2$  fold change values of the normalized expression data and the false-discovery rate corrected  $P$  values are provided in Supplementary Table 8. Finally, we note that although obtaining RNA samples at  $A_{600\text{nm}} \approx 1$  may be close to stationary phase, the inferred differential expressions of LPS and phospholipid-related genes are unlikely to be byproducts of the applied RNA sample extraction condition. Specifically, our conclusions remain after

excluding genes with potential stationary phase dependent expression from our analyses (see Supplementary Fig. 15). The set of stationary phase regulated genes ( $N = 449$ ) was compiled from literature<sup>54–56</sup> and by identifying those genes in our dataset whose expression level was significantly correlated ( $P < 0.05$ ) with  $A_{600\text{nm}}$  at the time of sample collection in our experiments.

The transcriptome data can be accessed from the Gene Expression Omnibus repository (<https://www.ncbi.nlm.nih.gov/geo/>) with the following access number: GSE96706.

**Functional analyses of differentially expressed genes.** To obtain a detailed functional annotation of the genes associated with outer membrane LPS and phospholipid synthesis, we selected the following gene ontology categories: lipid-A biosynthetic process (GO:0009245), extracellular polysaccharide biosynthetic process (GO:0045226), LPS biosynthetic process (GO:0009103), LPS core region biosynthetic process (GO:0009244), LPS transport (GO:0015920), phospholipid transport (GO:0015914) and phospholipid binding (GO:0005543). The selection was based on EcoGene 3.0 database<sup>48</sup>.

The category 'All LPS-related genes' includes all the genes that are associated with at least one of the following gene ontology categories: lipid-A biosynthetic process, extracellular polysaccharide biosynthetic process, LPS biosynthetic process, LPS core region biosynthetic process and LPS transport. The category 'All Phospholipid-related genes' includes all the genes that are associated with phospholipid transport or phospholipid binding gene ontology categories. Further information about the full gene sets is provided in Supplementary Table 9.

To investigate the upregulated LPS-related genes in more detail, we performed Fisher's exact tests on all resistant strains and all subcategories of LPS-related genes (Fig. 3c, left heatmap). In addition, Student's  $t$ -tests were used to identify differences in the average gene expression in a given gene ontology category among antibiotic-resistant strains grouped according to their antimicrobial peptide sensitivity (Fig. 3c, right heatmap, Supplementary Fig. 5).

**Chemogenomic screen. Competition experiment.** A high-throughput gene overexpression screen was performed to study the impact of upregulating each *E. coli* ORF on the susceptibility to a particular antimicrobial peptide (CAP18 and CP1). For a schematic workflow see Supplementary Fig. 6a. The screen was carried out using a well-established plasmid library (ASKA), where each *E. coli* ORF is cloned into a high copy number expression plasmid (pCA24N-ORF-GFP(-))<sup>55</sup>. A previously described, pooled version of the plasmid collection<sup>57</sup> was transformed into *E. coli* K-12 BW25113 strain by electroporation, as well as the empty plasmid pCA24N (without an ORF). The empty plasmid serves as a control to measure read counts that come from genomic DNA contamination during plasmid preparation (background). The resulting strain collection and the strain carrying the empty plasmid were grown in parallel in minimal salts medium and expression of the ORFs was induced mildly with a relatively low inducer concentration (100  $\mu\text{M}$  isopropyl- $\beta$ -D-thiogalactopyranoside). Following 1 h of incubation at  $30^\circ\text{C}$ , 500,000 cells from the library were used to inoculate each well of a 96-well microtiter plate pre-filled with a concentration gradient of the peptide in minimal salts media supplemented with 10  $\mu\text{g ml}^{-1}$  CHL and 100  $\mu\text{M}$  isopropyl- $\beta$ -D-thiogalactopyranoside, the same way as for a standard MIC measurement (described above). As a further control, both the library and the empty plasmid were also grown in the absence of peptide. Growth was monitored in a microplate reader (Biotek Synergy 2). Wells that showed 50% growth inhibition in late log phase were transferred into 20 ml minimal salts medium supplemented with the corresponding peptide. Peptide concentration was set again to result in 50% growth inhibition. Growth was stopped at late log phase ( $A_{600\text{nm}} > 1$ ). Following plasmid isolation, the samples were digested overnight with a mixture of lambda exonuclease and exonuclease I (Fermentas) at  $37^\circ\text{C}$  to remove genomic DNA contamination. The cleaned samples were subjected to next-generation sequencing with the SOLiD System (Life Technologies) to determine the diversity of the pooled library as described previously<sup>57</sup>. Each treatment was carried out in two replicates, except the untreated sample (in the absence of peptide), which had five replicates. The experiment with the empty plasmid was also carried out twice.

**Data analysis.** Raw sequence data processing and mapping onto *E. coli* ORFs were carried out the same way as in the whole transcriptome analysis. Raw sequence data were also mapped to the plasmid backbone. In order to make the mapped read counts comparable between the different samples, we carried out the following data processing workflow based on established protocols<sup>58,59</sup>, using a custom made R script: The extra read counts coming from the genomic DNA contamination (background) were estimated by assuming that the reads mapping to the unit length of the plasmid and the ORFs should have a ratio of 1:1. The total extra read count estimated thereof was partitioned among the ORFs based on their background frequency (that is, their relative frequency obtained from the experiment involving the empty plasmid). Next, these ORF-specific backgrounds were subtracted from the read counts. Then, a loglinear transformation was carried out on the background-corrected relative read counts. This transformation has the advantage over canonical logarithmic transformation of avoiding the inflation of data variance for ORFs with very low read counts<sup>60</sup>. The transformed relative read counts showed bimodal distributions (Supplementary Fig. 6b,c). The lower



mode (peak) of the distribution corresponds to ORFs that were not present in the sample. The upper mode represents those ORFs that grew unaffected by the overexpression. To make the different samples comparable, the two modes of the distribution of each sample were set to two predefined values. These values were chosen such that the original scale of the data was retained. In order to align the modes between samples, we introduced two normalization steps: one before and one after the loglinear transformation. The first normalization step identified the lower mode corresponding to the absent strains and shifted it to zero. Next, we performed the loglinear transformation step described above. The second normalization step was a linear transformation moving the upper mode to a higher predefined value. Following this normalization step, genes that were close to the lower mode in the untreated samples were discarded from the analysis as these represent strains that displayed poor growth even in the absence of drug treatment (that is, antimicrobial peptide sensitivity could not be reliably detected). Differential growth was calculated as the ratio of the normalized relative read counts in the treated and the non-treated samples at the end of the competition. Genes showing at least a twofold decrease in relative abundance in both replicates upon peptide treatment were considered as sensitizing genes.

In the next step, we examined the enrichment of CAP18- and CP1-sensitizing genes (Supplementary Table 10) in various gene ontology categories using Fisher's exact test. Obtained *P* values were corrected for multiple testing using the Benjamini & Hochberg method<sup>61</sup> (Supplementary Table 11).

**Real-time PCR analysis.** The *waaY* gene expression of the wild-type and *marR* mutant strains was determined by real-time RT-qPCR as described previously<sup>38</sup>. Briefly, quantitation of *cysG* expression level was applied as a reference standard across both samples<sup>62</sup>. RT-qPCR was performed in a Bio-Rad CFX96 Real Time System (Bio-Rad Laboratories). The PCR mixtures consisted of ~300 ng total RNA sample, 0.1 μM *waaY*\_FW-*waaY*\_REV primer pair (5'-ATCGATCTCTCCGAAAGC, 5'-CCTTTCAAACGCCGCATA) or 0.1 μM *cysG*\_FW-*cysG*\_REV reference primer pair (5'-TTGTCGGCGGTGGTGATGTC, 5'-ATGCGGTGAAGTGTGGAATAAACG)<sup>62</sup> and Verso one-step RT-qPCR Master Mix with low ROX reference dye (Thermo Scientific) in a final volume of 25 μl. The assay included 'non-template' and 'non-reverse transcription' controls to detect reagent contamination and presence of genomic DNA. The reverse transcription reaction was performed at 50°C for 15 min and the thermal profile of the PCR procedure repeated for 40 cycles was: 95°C for 10 min, 20 s denaturation at 95°C, 20 s annealing at 60°C and 60 s at 72°C coupled to data collection at the end of each amplification step. The dissociation curve consisted of 10 s incubation at 95°C, 5 s incubation at 65°C and ramp up to 95°C. Melting curves were used to validate product specificity. All samples were amplified in triplicate from the same total RNA preparation and the mean value was used for further analysis. Cycle threshold (Ct) values were determined using Bio-Rad CFX96 software.

The *waaY* expression level was calculated by relative messenger RNA quantitation, based on the mean of technical replicates, normalized to the expression level of the *cysG* control and taking into consideration the efficiency level of each primer pair. Each primer efficiency (*E*) was determined as  $E = 10^{-1/\text{slope}} - 1$ , based on the slope of four point standard curves with ten times concentration intervals, in duplicate, using wild-type strain RNA. Efficiency of *waaY* and *cysG* primer pairs was determined as 1.6 and 1.8, respectively. *waaY* expression level in the *marR* mutant strain was calculated relative to that of the wild-type strain as follows: Expression level =  $1.6^{(C_{\text{waaY\_WT}} - C_{\text{waaY\_marR}})} / (1.8^{(C_{\text{cysG\_WT}} - C_{\text{cysG\_marR}})})$ , and is presented as the mean of triplicates ± s.e.m.

**Measurement of antibiotic and PGLA combinations.** We selected PGLA antimicrobial peptide, which interacts with the bacterial LPS layer, and ten different antibiotics with a wide range of mechanisms of action (Supplementary Table 1). All experiments were conducted in the antibiotic-sensitive wild-type *E. coli* K-12 (BW25113) strains and in 21 different antibiotic-resistant strains adapted to 1 of 10 antibiotics (established in our previous work<sup>3</sup>) (Supplementary Table 12). Combination screens were performed in 96-well plates, using a liquid-handling robotic system (Hamilton Star workstation) to improve reproducibility.

Interactions between the two drugs were classified as synergistic, independent (additive) or antagonistic based on growth measurements at multiple concentration combinations (see below). Drug interaction was defined as deviation from non-interaction under the Loewe additivity model<sup>63</sup>, which assumes that a drug does not interact with itself. We followed a previously published protocol<sup>64</sup> with two important modifications. First, instead of examining all pairwise combinations of a predefined number of linearly increasing concentration points, we focused on a set of different antibiotic-PGLA relative concentration ratios and their dilution series (see Supplementary Fig. 16). This setup enabled us to efficiently sample the most informative regions of the two-dimensional concentration space. Second, we inferred drug interactions based on concentration combinations that led to 90% growth inhibitions (Supplementary Fig. 16). This enabled an especially robust detection of growth inhibition for antimicrobial peptides, which often exhibit steep dose-response curves that hinder precise measurement of, say, 50% inhibition concentrations.

As a first step, for each single agent (antibiotic and peptide alike), a 1.6-fold, eight-step dilution series was prepared with dose points determined based on the

MIC of the agents. The concentration range for each agent was between 10.5 times lower and 2.6 times higher than the MIC of the strain. Then, for each antibiotic-peptide pair we set up a 96-well plate as follows: we defined 7 different antibiotic/peptide relative concentration ratios (7:1, 3:1, 5:3, 1:1, 3:5, 1:3, 1:7) and generated dilution series thereof across the plate. As a result, each plate contained dilution series of seven antibiotic/peptide ratios, dilution series from the given antibiotic or peptide alone, four bacteria-free wells (no growth control) and four wells containing only medium without any drugs (growth control) (see Supplementary Fig. 16a).

Combination screen plates were inoculated with  $5 \times 10^4$  cells per well from overnight culture (grown at 30°C, with shaking at 300 rpm). The culture volume was 100 μl. Assay plates were incubated at 30°C with shaking at 300 rpm and bacterial growth was monitored by measuring the  $A_{600\text{nm}}$  of the liquid cultures after 24 h. We chose an incubation time of 24 hours in order to be able to discern condition-specific fitness defects from general costs of resistance of the antibiotic-resistant strains.

**Identifying interactions between antibiotics and PGLA.** To assess antagonism and synergy between pairs of antibiotics and PGLA in the sensitive wild type and in the antibiotic-resistant strains, we used the Loewe additivity model<sup>63</sup> which assumes that a drug does not interact with itself. To identify interactions for each pair of antibiotics and PGLA we first calculated relative inhibition values based on the initial  $A_{600\text{nm}}$  (maximum inhibition) and the average  $A_{600\text{nm}}$  of antibiotic-free control wells (maximum growth). Then, we identified those two concentration points for each antibiotic/peptide ratio where the inhibition of the growth was just above and below 90%, respectively. By fitting a linear model between these two concentration points we could interpolate the dosages for each antibiotic/peptide ratio that were responsible for the 90% growth inhibition (90% effective dosage: EC90%). Based on the Loewe model from the EC90% values of the single agents, we then calculated the theoretical EC90% dosages for each of the seven antibiotic/peptide ratios. Geometrically, the theoretical EC90% based on the Loewe model can be represented as a straight line between the EC90% of the single agents in the two-dimensional linear concentration space. Deviation of the shape of the lines connecting the experimentally measured EC90% from linearity indicates either synergy (concave isoboles) or antagonism (convex isoboles) (Supplementary Fig. 12). For each of the seven antibiotic/peptide ratios we defined the expected and the experimentally measured EC90% values. The combination index was calculated as: (theoretical EC90%)/(experimental EC90%) for each antibiotic/peptide ratio ( $CI_i$ ). The combination index for a given antibiotic and peptide pair was defined as the average of the combination index of the seven antibiotic/peptide ratios ( $\text{mean}(CI_{i_1}, CI_{i_2}, \dots, CI_{i_7})$ ). Where multiple independent experimental runs were available, we calculated the average value of the measured combination indexes.

Measurement errors of interaction screens were estimated from two independent experimental runs of 24 combinations by calculating the pooled variance (standard deviation) of the combination indexes of the replicate experiments. The cut-off values were defined as  $1.95 \times \text{s.d.}$  value of the combination index. The cut-off values were as follows: combination index  $\geq 1.14$  for antagonism; combination index  $\leq 0.86$  for synergism; and  $0.86 < \text{combination index} < 1.14$  for no interaction.

**Experimental evolution of resistance.** Experimental evolution was performed based on a previously established automated evolution experiment<sup>65,66</sup> during approximately 160 generations (24 transfers). Ten parallel independent cultures were propagated in eight experimental conditions such as TET or CPR in the presence or absence of  $\frac{1}{2}$  and  $\frac{1}{4}$  of the MIC of PGLA; TOB in the presence or absence of  $\frac{1}{2}$  and  $\frac{1}{4}$  of the MIC of the BAC5; as well as  $\frac{1}{2}$  and  $\frac{1}{4}$  of the MIC of PGLA and  $\frac{1}{2}$  and  $\frac{1}{4}$  of the MIC of BAC5, alone. Chess-board layout was used on the plate to monitor potential cross-contamination events. Starting with subinhibitory drug concentration, each culture was allowed to grow for 24 hours. Twenty microlitres of culture was transferred to four independent wells containing fresh medium and increasing dosages of antibiotic ( $0.5 \times$ ,  $1 \times$ ,  $1.5 \times$  and  $2.5 \times$  the concentration of the previous step). At each transfer, cell growth was monitored by measuring the  $A_{600\text{nm}}$  value (Biotek Synergy 2 microplate reader was used for this purpose). Only populations of the highest drug concentration that reached  $A_{600\text{nm}} > 0.2$  were selected for further evolution. Accordingly, only one of the four populations was retained for each independently evolving lineage. This protocol was designed to avoid population extinction and to ensure that populations with the highest level of resistance were propagated further during evolution.

**Reporting Summary.** Further information on experimental design is available in the Nature Research Reporting Summary linked to this article.

**Data availability.** The transcriptome data can be accessed from the Gene Expression Omnibus repository (<https://www.ncbi.nlm.nih.gov/geo/>) with access number GSE96706.

The following excel files are provided as supplementary items in separated files: Supplementary Table 2 – The list of antimicrobial peptides employed in this study and the available information about them based on literature mining.



Supplementary Table 3 – Dataset of collateral sensitivity and cross-resistance interactions identified at the level of antibiotic-resistant strains.

Supplementary Table 4 – Relative changes in the minimum inhibitory concentrations (MIC) of the antimicrobial peptides towards antibiotic-resistant strains.

Supplementary Table 6 – List of the main chemical and physical properties of the antimicrobial peptides employed in this study.

Supplementary Table 7 – Susceptibility profiles of antibiotic-resistant *E. coli* clinical isolates across antimicrobial peptides.

Supplementary Table 8 – Differential expression analysis of RNA-Seq data of 24 antibiotic-resistant strains.

Supplementary Table 9 – Bile acid sensitivity of the antibiotic-resistant strains and list of genes involved in phospholipid and LPS synthesis.

Supplementary Table 10 – List of genes sensitizing towards CAP18 and CP1 in the chemogenomic study but not to control peptide CP1.

Supplementary Table 13 – Combination index (CI) values of PGLA–antibiotic (AB) combinations on *E. coli* clinical isolates and respective antibiotic-resistant strains.

Supplementary Table 14 – Mutation-incorporating pORTMAGE oligonucleotides, allele-specific colony-PCR, HRM PCR and sequencing primers.

Received: 23 May 2017; Accepted: 17 April 2018;

Published online: 24 May 2018

## References

- Imamovic, L. & Sommer, M. O. Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development. *Sci. Transl. Med.* **5**, 204ra132 (2013).
- Lázár, V. et al. Genome-wide analysis captures the determinants of the antibiotic cross-resistance interaction network. *Nat. Commun.* **5**, 4352 (2014).
- Lázár, V. et al. Bacterial evolution of antibiotic hypersensitivity. *Mol. Syst. Biol.* **9**, 700–700 (2013).
- Toprak, E. et al. Evolutionary paths to antibiotic resistance under dynamically sustained drug selection. *Nat. Genet.* **44**, 101–105 (2012).
- Palmer, A. C. & Kishony, R. Understanding, predicting and manipulating the genotypic evolution of antibiotic resistance. *Nat. Rev. Genet.* **14**, 243–248 (2013).
- Pál, C., Papp, B. & Lázár, V. Collateral sensitivity of antibiotic-resistant microbes. *Trends Microbiol.* **23**, 401–407 (2015).
- Jenssen, H., Hamill, P. & Hancock, R. E. W. Peptide antimicrobial agents. *Clin. Microbiol. Rev.* **19**, 491–511 (2006).
- Fjell, C. D., Hiss, J. A., Hancock, R. E. & Schneider, G. Designing antimicrobial peptides: form follows function. *Nat. Rev. Drug Discov.* **11**, 37–51 (2012).
- Mahlapu, M., Håkansson, J., Ringstad, L. & Björn, C. Antimicrobial peptides: an emerging category of therapeutic agents. *Front. Cell. Infect. Microbiol.* **6**, 194 (2016).
- Andersson, D. I., Hughes, D. & Kubicek-Sutherland, J. Z. Mechanisms and consequences of bacterial resistance to antimicrobial peptides. *Drug Resist. Updat.* **26**, 43–57 (2016).
- Melo, M. N., Ferre, R. & Castanho, M. A. R. B. Antimicrobial peptides: linking partition, activity and high membrane-bound concentrations. *Nat. Rev. Microbiol.* **7**, 245 (2009).
- Alves, C. S. et al. *Escherichia coli* cell surface perturbation and disruption induced by antimicrobial peptides BP100 and pepR. *J. Biol. Chem.* **285**, 27536–27544 (2010).
- Avitabile, C., D'Andrea, L. D. & Romanelli, A. Circular dichroism studies on the interactions of antimicrobial peptides with bacterial cells. *Sci. Rep.* **4**, 4293 (2014).
- Soriano, F., Ponte, C., Santamaria, M. & Jimenez-Arriero, M. Relevance of the inoculum effect of antibiotics in the outcome of experimental infections caused by *Escherichia coli*. *J. Antimicrob. Chemother.* **25**, 621–627 (1990).
- Bechinger, B., Zasloff, M. & Opella, S. J. Structure and dynamics of the antibiotic peptide PGLa in membranes by solution and solid-state nuclear magnetic resonance spectroscopy. *Biophys. J.* **74**, 981–987 (1998).
- Ostorhazi, E., Nemes-Nikodem, E., Knappe, D. & Hoffmann, R. In vivo activity of optimized apidaecin and onocin peptides against a multiresistant KPC-producing *Klebsiella pneumoniae* strain. *Prot. Pept. Lett.* **21**, 368–373 (2014).
- Proctor, R. A. et al. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. *Nat. Rev. Micro.* **4**, 295–305 (2006).
- Munck, C., Gumpert, H. K., Wallin, A. I., Wang, H. H. & Sommer, M. O. Prediction of resistance development against drug combinations by collateral responses to component drugs. *Sci. Transl. Med.* **6**, 262ra156 (2014).
- Matiuzzo, M. et al. Role of the *Escherichia coli* SbmA in the antimicrobial activity of proline-rich peptides. *Mol. Microbiol.* **66**, 151–163 (2007).
- Pages, J.-M., James, C. E. & Winterhalter, M. The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria. *Nat. Rev. Micro.* **6**, 893–903 (2008).
- Fernández, L. & Hancock, R. E. W. Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance. *Clin. Microbiol. Rev.* **25**, 661–681 (2012).
- Seoane, A. S. & Levy, S. B. Characterization of MarR, the repressor of the multiple antibiotic resistance (*mar*) operon in *Escherichia coli*. *J. Bacteriol.* **177**, 3414–3419 (1995).
- Davin-Regli, A. et al. Membrane permeability and regulation of drug “influx and efflux” in enterobacterial pathogens. *Curr. Drug Targets* **9**, 750–759 (2008).
- Gutsmann, T., Fix, M., Larrick, J. W. & Wiese, A. Mechanisms of action of rabbit CAP18 on monolayers and liposomes made from endotoxins of phospholipids. *J. Membr. Biol.* **176**, 223–236 (2000).
- Kitagawa, M. et al. Complete set of ORF clones of *Escherichia coli* ASKA library (A complete Set of *E. coli* K-12 ORF Archive): unique resources for biological research. *DNA Res.* **12**, 291–299 (2006).
- Delcour, A. H. Outer membrane permeability and antibiotic resistance. *BBA Proteins Proteom.* **1794**, 808–816 (2009).
- Bociek, K. et al. Lipopolysaccharide phosphorylation by the WaaY kinase affects the susceptibility of *Escherichia coli* to the human antimicrobial peptide LL-37. *J. Biol. Chem.* **290**, 19933–19941 (2015).
- Lee, J.-H., Lee, K.-L., Yeo, W.-S., Park, S.-J. & Roe, J.-H. SoxRS-mediated lipopolysaccharide modification enhances resistance against multiple drugs in *Escherichia coli*. *J. Bacteriol.* **191**, 4441–4450 (2009).
- Gonzales, P. R. et al. Synergistic, collaterally sensitive  $\beta$ -lactam combinations suppress resistance in MRSA. *Nat. Chem. Biol.* **11**, 855 (2015).
- Baym, M., Stone, L. K. & Kishony, R. Multidrug evolutionary strategies to reverse antibiotic resistance. *Science* **351**, aad3292 (2016).
- Oz, T. et al. Strength of selection pressure is an important parameter contributing to the complexity of antibiotic resistance evolution. *Mol. Biol. Evol.* **31**, 2387–2401 (2014).
- Horinouchi, T. et al. Prediction of cross-resistance and collateral sensitivity by gene expression profiles and genomic mutations. *Sci. Rep.* **7**, 14009 (2017).
- Pena-Miller, R. et al. When the most potent combination of antibiotics selects for the greatest bacterial load: The smile-frown transition. *PLoS Biol.* **11**, e1001540 (2013).
- Avan, I., Hall, C. D. & Katritzky, A. R. Peptidomimetics via modifications of amino acids and peptide bonds. *Chem. Soc. Rev.* **43**, 3575–3594 (2014).
- Jiao, Y. J., Baym, M., Veres, A. & Kishony, R. Population diversity jeopardizes the efficacy of antibiotic cycling. Preprint at <https://www.biorxiv.org/content/early/2016/10/20/082107> (2016).
- Fleitas, O. & Franco, O. L. Induced bacterial cross-resistance toward host antimicrobial peptides: a worrying phenomenon. *Front. Microbiol.* **7**, 381 (2016).
- Kubicek-Sutherland, J. Z. et al. Antimicrobial peptide exposure selects for *Staphylococcus aureus* resistance to human defence peptides. *J. Antimicrob. Chemother.* **72**, 115–127 (2016).
- Nyerges, Á. et al. A highly precise and portable genome engineering method allows comparison of mutational effects across bacterial species. *Proc. Natl Acad. Sci.* **113**, 2502–2507 (2016).
- Baba, T. et al. Construction of *Escherichia coli* K-12 in-frame, single-gene knockout mutants: the Keio collection. *Mol. Syst. Biol.* **2**, 2006 (2006).
- Tenaillon, O. et al. Tempo and mode of genome evolution in a 50,000-generation experiment. *Nature* **536**, 165 (2016).
- Malouin, F., Chamberland, S., Brochu, N. & Parr, T. R. Influence of growth media on *Escherichia coli* cell composition and ceftazidime susceptibility. *Antimicrob. Agents Chemother.* **35**, 477–483 (1991).
- Yeaman, M. R. & Yount, N. Y. Mechanisms of antimicrobial peptide action and resistance. *Pharmacol. Rev.* **55**, 27–55 (2003).
- Wiegand, I., Hilpert, K. & Hancock, R. E. W. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. *Nat. Protoc.* **3**, 163–175 (2008).
- Bates, D., Machler, M., Bolker, B. M. & Walker, S. C. Fitting linear mixed-effects models using lme4. *J. Stat. Softw.* <https://doi.org/10.18637/jss.v067.i01> (2015).
- Bolker, B. M. et al. Generalized linear mixed models: a practical guide for ecology and evolution. *Trends Ecol. Evol.* **24**, 127–135 (2009).
- Méhi, O. et al. Perturbation of iron homeostasis promotes the evolution of antibiotic resistance. *Mol. Biol. Evol.* **31**, 2793–2804 (2014).
- Karcagi, I. et al. Indispensability of horizontally transferred genes and its impact on bacterial genome streamlining. *Mol. Biol. Evol.* **33**, 1257–1269 (2016).
- Zhou, J. & Rudd, K. E. EcoGene 3.0. *Nucleic Acids Res.* **41**, D613–D624 (2013).
- R Core Team. *R: A Language and Environment for Statistical Computing* (R Foundation for Statistical Computing, Vienna, Austria, 2014).

50. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* **26**, 139–140 (2010).
51. Robinson, M. D. & Oshlack, A. A scaling normalization method for differential expression analysis of RNA-seq data. *Genome Biol.* **11**, R25 (2010).
52. Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res.* **43**, e47 (2015).
53. Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E. & Storey, J. D. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. *Bioinformatics* **28**, 882–883 (2012).
54. Chang, D. E., Smalley, D. J. & Conway, T. Gene expression profiling of *Escherichia coli* growth transitions: an expanded stringent response model. *Mol. Microbiol.* **45**, 289–306 (2002).
55. Tjaden, B. et al. Transcriptome analysis of *Escherichia coli* using high-density oligonucleotide probe arrays. *Nucleic Acids Res.* **30**, 3732–3738 (2002).
56. Dong, T. & Schellhorn, H. E. Control of RpoS in global gene expression of *Escherichia coli* in minimal media. *Mol. Genet. Genom.* **281**, 19–33 (2009).
57. Notebaart, R. A. et al. Network-level architecture and the evolutionary potential of underground metabolism. *Proc. Natl Acad. Sci.* **111**, 11762–11767 (2014).
58. Pierce, S. E., Davis, R. W., Nislow, C. & Giaever, G. Genome-wide analysis of barcoded *Saccharomyces cerevisiae* gene-deletion mutants in pooled cultures. *Nat. Protoc.* **2**, 2958–2974 (2007).
59. Robinson, D. G., Chen, W., Storey, J. D. & Gresham, D. Design and analysis of Bar-seq experiments. *G3* **4**, 11–18 (2014).
60. Rocke, D. M. & Durbin, B. Approximate variance-stabilizing transformations for gene-expression microarray data. *Bioinformatics* **19**, 966–972 (2003).
61. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J. Royal Stat. Soc. Ser. B Methodol.* **57**, 289–300 (1995).
62. Zhou, K. et al. Novel reference genes for quantifying transcriptional responses of *Escherichia coli* to protein overexpression by quantitative PCR. *BMC Mol. Biol.* **12**, 18 (2011).
63. Loewe, S. The problem of synergism and antagonism of combined drugs. *Arzneimittelforschung* **3**, 285–290 (1953).
64. Cokol, M. et al. Systematic exploration of synergistic drug pairs. *Mol. Syst. Biol.* **7**, 544–544 (2011).
65. Suzuki, S., Horinouchi, T. & Furusawa, C. Prediction of antibiotic resistance by gene expression profiles. *Nat. Commun.* **5**, 5792 (2014).
66. Bódi, Z. et al. Phenotypic heterogeneity promotes adaptive evolution. *PLoS Biol.* **15**, e2000644 (2017).
67. Murtagh, F. & Legendre, P. Ward's hierarchical agglomerative clustering method: Which algorithms implement Ward's criterion? *J. Classif.* **31**, 274–295 (2014).

## Acknowledgements

The authors thank É. Kondorosi for providing the cationic antimicrobial peptide NCR335, and M.O.A. Sommer for the clinical isolates. The authors also acknowledge the following financial support: the Hungarian Academy of Sciences Postdoctoral Fellowship Programme (V.L.), the Hungarian Scientific Research Fund NKFI PD 116222 (A.M.), NKFI 120220 (B.K.), OTKA PD 109572 (B.C.) and NKFI FK 124254 (O.M.), the 'Lendület' Programme of the Hungarian Academy of Sciences and The Wellcome Trust (B.P. and C.P.), the European Research Council H2020-ERC-2014-CoG 648364 - Resistance Evolution (C.P.), GINOP-2.3.2-15-2016-00014 (EVOMER), GINOP-2.3.2-15-2016-00020 (MolMedEx TUMORDNS) and GINOP-2.3.3-15-2016-00001. I.N. and B.K. were supported by the János Bolyai Research Scholarship of the Hungarian Academy of Sciences and Á.N. by the Ph.D. fellowship of the Boehringer Ingelheim Fonds.

## Author contributions

C.P. and B.P. conceived and supervised the project. V.L. and A.M. designed the experiments and developed data analysis procedures. C.P., B.P., V.L., A.M. and R.S. wrote the paper. R.S., A.K., A.D., F.W. and M.D. performed the zeta potential measurements. G.O., Z.H. and T.A.M. synthesized the peptides magainin 2 and anginex. R.S. and O.M. purified RNA for transcriptomic analysis. B.B. and I.N. performed RNA-Seq experiments. P.K.J., G.F., M.S. and B.K. generated and analysed the chemogenomic data. E.U. isolated and identified *E. coli* clinical isolates. B.C. and Á.N. prepared the mutant strains. V.L., L.D., A.M., R.S. and B.C. contributed to all other experiments. V.L., A.M., G.G., G.F. and A.G. analysed and interpreted the data.

## Competing interests

The authors declare no competing interests. B.B. and I.N. had consulting positions at SeqOmics Biotechnology Ltd. at the time the study was conceived. SeqOmics Biotechnology Ltd. was not directly involved in the design and execution of the experiments or in the writing of the manuscript. This does not alter the author's adherence to all the Nature policies on sharing data and materials.

## Additional information

**Supplementary information** is available for this paper at <https://doi.org/10.1038/s41564-018-0164-0>.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Correspondence and requests for materials** should be addressed to B.P. or C.P.

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## Life Sciences Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.

For further information on the points included in this form, see [Reporting Life Sciences Research](#). For further information on Nature Research policies, including our [data availability policy](#), see [Authors & Referees](#) and the [Editorial Policy Checklist](#).

### ▶ Experimental design

#### 1. Sample size

Describe how sample size was determined.

In all experiments we followed previously established protocols and sample sizes that are typically used in the literature: systematic measurement of antimicrobial peptide susceptibilities (Lázár et al 2013), minimum inhibitory concentration (MIC) measurements (Wiegand et al 2008), kill curve assay (Chalkley and Koornhof 1985), whole transcriptome sequencing (Karcagi et al 2016), real-time PCR analysis (Nyerges et al 2016), combination measurements (Loewe 1953), experimental evolution (Suzuki et al 2014, Bódi et al 2017), promoter activity measurement (Zaslaver et al 2006), competition assay (Chait et al 2007), zeta potential measurement (Alves et al 2010), poly-L-lysine binding assay (Peschel et al 1999).

#### 2. Data exclusions

Describe any data exclusions.

In the whole transcriptome sequencing and data analysis raw sequence data was size-selected by discarding reads shorter than 50bp. This filtering was applied to ensure maximum read quality and consistent read mapping parameters. During the analysis of association of upregulation of membrane-associated genes and collateral sensitivity (represented in Figure 3C) peptides with too few (<4) or too many (>21) collateral sensitivity (CS) interactions were excluded as the sample size in either the CS or the NotCS group was not sufficient for statistical analysis (sample size calculation with  $\alpha=0.1$ ,  $\text{power}=0.8$ ,  $\text{delta}=2$ ,  $\text{SD}=1$ ). These exclusions are now described in more details in the Materials and Methods section. In both cases the exclusion criteria were pre-established.

#### 3. Replication

Describe whether the experimental findings were reliably reproduced.

All attempts at replication were successful

#### 4. Randomization

Describe how samples/organisms/participants were allocated into experimental groups.

Samples were not allocated into experimental groups

#### 5. Blinding

Describe whether the investigators were blinded to group allocation during data collection and/or analysis.

Samples were not allocated into experimental groups

Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.

## 6. Statistical parameters

For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).

n/a Confirmed

- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
- A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- A statement indicating how many times each experiment was replicated
- The statistical test(s) used and whether they are one- or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
- A description of any assumptions or corrections, such as an adjustment for multiple comparisons
- The test results (e.g.  $P$  values) given as exact values whenever possible and with confidence intervals noted
- A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
- Clearly defined error bars

See the web collection on [statistics for biologists](#) for further resources and guidance.

## ► Software

Policy information about [availability of computer code](#)

### 7. Software

Describe the software used to analyze the data in this study.

CLC Genomic Workbench tool version 7.5.1, RStudio version 1.1.383, R version 3.0.2 with packages edgeR (3.4.2), limma (3.18.1), sva (3.8.0), R version 3.3.1 with packages lmtest (0.9-35), pscl (1.5.2), R version 3.4.3 with packages lme4 (1.1-15), aggregation (1.0.1), RVAideMemoire (0.9-69), gplots (3.0.1), R version 3.4.4 with packages ROCR (1.0-7), lawstat (3.2), parmigene (1.0.2), fpc (2.1-11), amap (0.8-14), RColorBrewer (1.1-2), ggplot (2.2.1), Graph Pad Prism 5.0, Adobe Illustrator CC 2017

For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). [Nature Methods guidance for providing algorithms and software for publication](#) provides further information on this topic.

## ► Materials and reagents

Policy information about [availability of materials](#)

### 8. Materials availability

Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.

Antimicrobial peptides are available from custom synthesis at ProteoGenix. All other materials were from standard commercial sources.

### 9. Antibodies

Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).

No antibodies were used

### 10. Eukaryotic cell lines

a. State the source of each eukaryotic cell line used.

No eukaryotic cell lines were used.

b. Describe the method of cell line authentication used.

No eukaryotic cell lines were used.

c. Report whether the cell lines were tested for mycoplasma contamination.

No eukaryotic cell lines were used.

d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by [ICLAC](#), provide a scientific rationale for their use.

No eukaryotic cell lines were used.



## ► Animals and human research participants

---

Policy information about [studies involving animals](#); when reporting animal research, follow the [ARRIVE guidelines](#)

### 11. Description of research animals

Provide details on animals and/or animal-derived materials used in the study.

No animals were used.

Policy information about [studies involving human research participants](#)

### 12. Description of human research participants

Describe the covariate-relevant population characteristics of the human research participants.

The study did not involve human research participants.